michigan cv - Case Western Reserve University - School of Medicine

CURRICULUM VITAE 

Alvin Harold Schmaier 

CV Date 7/16/2012 Version 

EDUCATION: 

High School: Asbury Park HS, Asbury Park, N.J. 1962-66 

Undergraduate: University of Virginia, Charlottesville, VA, 1966-70, B.A. in Philosophy 

Medical School: Medical College of Virginia, Virginia Commonwealth 

University, Richmond, VA, 1970-74, M.D. 

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS: 

7/74-6/75 Intern in Internal Medicine, Temple University Hospital, 

Philadelphia, Pennsylvania 

7/75-6/77 Resident in Internal Medicine, Temple University Hospital, 

Philadelphia, Pennsylvania 

7/77-6/79 Fellow in Hematology/Oncology, Department of Medicine, 

Hospital of the University of Pennsylvania, Philadelphia, PA 

7/79-6/80 Research Fellow, Specialized Center for Thrombosis Research, 

Temple University School of Medicine, Philadelphia, PA 

FACULTY APPOINTMENTS: 

7/79-6/80 Clinical Instructor, Department of Medicine 

Temple University Hospital, Philadelphia, PA 

7/80-6/86 Assistant Professor, Department of Medicine, 


7/81 Assistant Professor, Thrombosis Research Center, 


7/82 Assistant Professor, Department of Pathology, 


7/86-6/91 Associate Professor, Department of Medicine, 


7/91 8/91 Professor, Department of Medicine 


8/91-11/05 Professor, Department of Internal Medicine 

The University of Michigan, Ann Arbor, MI 

8/91 Adjunct Professor of Thrombosis 

Temple University School of Medicine, Philadelphia PA 

7/97-11/05 Professor, Department of Pathology 

The University of Michigan, Ann Arbor, MI 

12/05-Present Professor, Department of Medicine 

Case Western Reserve University, Cleveland, OH 

4/06-Present Robert W. Kellermeyer, MD Professor of Oncology 


12/05-10/09 Chief, Division of Hematology/Oncology, Department of Medicine 

University Hospitals Case Medical Center, Cleveland, OH 

2006-Present Professor, Division of General Medical Sciences, Cancer Center 


2006-2010 Trainer, Department of Pharmacology, Case Western Reserve U 

2007-Present Professor, Department of Pathology, Case Western Reserve U 

CONSULTING POSITIONS: 

Scios Inc., Mountain View CA-1994-99 

Thromgen, Inc., Ann Arbor MI-1995-2008: Founder, President, CE0 

Merck Pharmaceuticals, 1996 

Accumed Systems, Inc., Scientific Advisory Board, 1997-02 

Smith Kline Beecham Pharmaceuticals, 1998 

Warner Lambert, Parke Davis, 1998-00

CURRICULUM VITAE 2 Alvin H. Schmaier 

3 M Health Care, Cardiovascular System, 1999 

Schering Plough, Inc., 1999 

Pfizer, Terumo, Pharmacia, 2001 

Pfizer, Pharmacia, 2002 

Dade-Behring 2003-2005 

Dyax Corp. 2004 

Soma Logic 2004 

Biomeriux, 2005 

BD Science , 2008 

CSL Behring, 2008 

Dyax Corp, 2009 

Cubist Pharmaceuticals, 2009 

SCIENTIFIC ACTIVITIES: 

Local: Reviewer, Fellows Forum, Department of Medicine, 1991 

Peer Review Committee, SE PA Affiliate of AHA, 1988-1991 

Peer Reviewer, Research Fellowships, MI Affiliate of AHA, '92-'95 

Vice Chairman Res Fellowship Committee of MI AHA, '93-94 

Chairman, Res Fellowship Committee of MI AHA, '95-'96 

Research Committee, MI AHA, ‘94-’97 

Peer Reviewer, Regional AHA Committee, ‘98 

National: Peer Reviewer, VA Merit Review Board in Hematology, '89-93 

Chairman:VA Merit Review Board in Hematology, '92-93 

American Heart Association: Council of Thrombosis 

Executive Committee Council of Thrombosis, '93-95 

Reviewer: TRDRP-University of California, 1993-94 

NHLBI: Hematology Study Section 2 - Special Reviewer, 1996 

NHLBI: Hematology-2 Special Emphasis Panel, 1998 

Amer. Heart Assoc., Great American Consortium Group 2, 1999 

NHLBI: Clinical Trials Review Committee, 1999 

Amer. Heart Assoc., Great American Consortium Group 2, 2000-2001 

NIGMS: Special Emphasis Panel, Clinical Trials 2000 

Amer. Heart Assoc., Great American Consortium Group 2, 2001 

Co-Chairman 

NHLBI: ZRG1 Hem-2 Study Section, 2001-2004 

NHLBI: PPG Review Committee, 2002 

NHLBI: R24 Special Emphasis Panel ZHL1 CSR-D F1, 11/25/02: Chairman 

NHLBI: HT, Special Emphasis Panel, 11/13/03 

NHLBI: HT, Hemostasis & Thrombosis Study Section, 2004-Present 

NHLBI ZGM1 TB-6, Special Emphasis Panel, 2004 

NHLBI ZHL1 CCT-A (C1) Special Emphasis Panel, 2005 

NHLBI HLBP Workgroup, 2006 

Clin Lab Standards Institute, Subcommittee on Platelet Function Testing, 2006 

NHLBI HLBP Workgroup, 2007 

NHLBI ZRG1 HEME-D, June, 2007 

NHLBI: R24 Special Emphasis Panel ZHL1 CSR-D F1, 4/3/08: Chairman 

NHLBI: ZRG1 HEMT-D 01 SI0, 10/24/08 

NIGMS: ZGM1 PPBC-5 (BT), 4/15/09 

NIH/NHLBI ZHL1 CSR-U (Mentored Science Research Awards-K08), 10/8-9/09 

NIH/NHLBI ZRG1 VH-E (Clinical Hematology), 10/30/09 




NIH/NHLBI ZHL1 CCT-B C2 1, Loan Repayment Program Review 5/4/2011 

American Society Hematology-Research Training Award Committee, 2010-2012 



NIH/NHLBI ZHL1 CSR-U (Mentored Science Research Awards-K080 2/16-17/12


NIH 2021/08 ZCA1 PCRB-A(A2)B-Ped Res-Loan Repayment Prog 5/7/2012 

NIH/NHLBI ZHL1 CSR-U (Mentored Science Research Awards-K080 6/21-22/12 

American Society Hematology-ASH Scholar Study Section, 2012 

International: ISTH, Scientific and Standardization Committee Class of 2006 

ISTH: Scientific and Standardization Committee’s Publication Review Committee 

2003-2004 

ISTH, Co-Chair, Plasma Kallikrein-Kinin System subcommittee 2008-2009 

2009: Technology Foundation, Utrecht, Netherlands – grant reviewer 

2012: European Research Council LS4 panel (Physiology, Pathophysiology and 

Endocrinology) 

Journal Reviewer: J of Clinical Investigation, Blood, J of Biological Chemistry, Laboratory Investigation, 

New England Journal of Medicine, Thrombosis and Haemostasis, Thrombosis Research, Journal of Immunology, 

Journal of Laboratory Clinical Medicine, Analytic Biochemistry, Biochemical Journal, J. Cell Biology, Amer. J. Clin. 

Pathology, Biochemistry, Life Sciences, Hypertension, J. Exper. Pharm. Therapeutics, Biochim Biophys Acta, Amer. 

J. Physiol, Circulation Research, J. Applied Physiology, Atherosclerosis Thrombosis & Vascular Biology; Amer J. 

Hematology; Fibrinolysis; Brit. J.Pharmacology; NCI Journal; Circulation; Amer. J. Pathol; Neoplasia; Breast Cancer 

Research and Treatment; Blood Coagulation and Fibrinolysis; J of Leukocyte Biology; J of Neuroopthalomology, 

Mayo Clinic Proceedings, Cytology, Biological Chemistry, J of Thrombosis and Hemostasis; Peptides, BBRC; 

Biochem Pharmacol; Nature Medicine; FEBS Journal; Atherosclerosis; J Mol Medicine; Brit J Pharmacology; Nature 

Reviews Cardiology; Biorheology; 

Journal Advisory Board: Journal of Thrombosis and Haemostasis, 2001-2002 

Journal Editorial Board: Thrombosis and Haemostasis, 2002-2007: Section Editor 

Journal Advisory Board: Journal of Thrombosis and Haemostasis, 2008-2012 

Guest Editor: Proceedings National Academy of Science, 2012. 

GRANT SUPPORT (Current): 

RO1-HL52779-15, 2010-2014, "Regulation of Kinin Delivery on HUVEC", A.H. Schmaier, P.I. 

($1,530,000 Total Costs), 3.6 mo salary support. 

American Society of Hematology: 7/1/09-6/30/12, “Special Training Fellowship Program in 

Benign Hematology” ($50,000 Total costs), A.H. Schmaier, P.I. (no salary support). 

CSL Behring, LLC, 7/1/10-6/30/12, “C1 INH Preserves Stored Platelet Function” ($117,833 Total 

Costs).A.H. Schmaier, P.I., 1.2 mo salary support. 

5K12 CA076917-10, 7/1/08-6/30/13, “Clinical Oncology Research Career Development Program 

(CORP), S.L. Gerson, P.I. ($3,768,981 Total Costs), A. Schmaier, Co-P.I., 1.2 mo salary support 

U01 AG034661-01, 09/30/09-06/30/12, “PACTTE-Partnership for Anemia”, N. Berger, P.I.,0.6 calendar mo 

salary support, A. Schmaier, C0-P.I. 

1U01 HL072033-06, 01/1/11-08/31/14, “Transfusion Medicine/Hemostasis Clinical Research Network”, K.R. 

McCrae, P.I. 0.6 calendar mo salary support, A. Schmaier, Co-P.I. 

R21-HL112666, 04/01/12-3/31/14, “Prolylcarboxypeptidase is a Risk Factor for Cardiovascular Disease” 

($235,500 Total Costs), A. Schmaier, P.I., 0.6 calendar mo salary support. 

CLINICAL TRIALS (Current): 

BAY 1Z08, Bayer, Randomized, Controlled, Parallel, Prospective Trial to Evaluate the Effect of 

Secondary Prophylaxis with rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects, as 

Applicable, Compared to that of Episodic Treatment. 1 patient enrolled in 2010-2013. 

GRANT SUPPORT (Past): 

R43 HL086038-01, 2006-2007, “Enhancing Thrombostatin’s Oral Delivery”, J.M. Hilfinger, P.I., 

($54,075 Total Costs) 

R44-HL55709-04, 2005-2008, “Thrombostatin-A Thrombin Receptor Inhibitor”, A.H. Schmaier, 

P.I., ($1,498,849 Total Costs) 

Accumetrics P95069, 10/1/07-9/30/08, “Reference Range Study: Assessment of Platelet Function 

in Subjects in the Hospital Population, A.H. Schmaier, P.I. ($23,000 Total Costs) 

R01 HL070766-05, 2006-2009, “Procoagulant Microparticles: Novel Determinants of Venous 

Thrombosis, T.W. Wakefield, P.I., ($119,841 Total costs over 3 years), A. Schmaier, Co-P.I. 

5R01 HL085816-03, 08/22/07-06/30/11, “MRP-14 and Cardiovascular Disease”, D. Simon, P.I. 0.3 calendar 

mo


salary support, A. Schmaier, Co-P.I. 

BAX 1Z08, Baxter, FEIBA NF: A Prospective Open-Label, Randomized, Parallel Study to Evaluate Efficacy 

and Safety of Prophylactic Versus On-Demand Treatment in Subjects with Hemophilia A or B and a High Titer Inhibitor. 2 

patients enrolled in 2010-2011. 

and 

SPECIALTY CERTIFICATION AND LICENSURE: 

Certifications: 

1977 American Board of Internal Medicine, #59176 

1980 Subspecialty, Hematology, #59176 

1981 Subspecialty, Oncology, #59176 

Medical Licensure: 

Pennsylvania 1975-1991, MD 

Michigan 1991-2007, MD 

Ohio 2006-Present, MD 

MILITARY SERVICE: None 

HONORS AND AWARDS: 

1967 Alpha Epsilon Delta, University of Virginia 

1969 Intermediate Honors, University of Virginia 

1970 B.A. with Distinction, University of Virginia 

1972 NIH Pediatric Hematology Summer Fellowship 

1973 First Prize for Research Presentation, Med Coll of VA 

1974 Lee Sutton Prize for Excellence in Pediatrics, Med Coll of VA 

1979 NIH Fellowship F32 HL05925, 7/79-6/80 

1980 NIH Clinical Investigator Award 1 KO8 HL00694, 7/80-12/85 

1983 Department of Medicine Representative to AFCR, Temple University 

1987 NIH Research Career Development Award HL01615, 7/87-6/92, 

1991 The E.K Frey-E. Werle Promotion Prize 

1998 Visiting Professor - Peking Union Med Coll Beijing, P.R. China 

1999 Invited Speaker, Brazilian Biochemistry Society, Caxambu, Brazil 5/24/99 

2004 Invited Speaker, Brazilian Soc of Clinical Pathology, Florianopolis, Brazil 9/22/04 

Distinguished Visiting Professor, Heart and Stroke Center, U. of Toronto 10/18/04 

2007 Appointed to the Robert W. Kellermeyer Chair in Oncology, University Hospitals 

Case Western Reserve University 

2011 Cleveland Magazine “Best Doc” 

2012 Cleveland Magazine “Best Doc” 

MEMBERSHIPS AND OFFICES IN PROFESSIONAL SOCIETIES: 

1981 American Federation of Clinical Research 

1982 American Heart Association/Council on Thrombosis 

Executive Committee, 1993-95 

Delegate for Council of Thrombosis to AHA Futures Conference, June, 1994 

American Society of Hematology 

1983 Sigma Xi 

1985 International Society of Thrombosis and Haemostasis 

Co-chairman, Subcommittee on Contact Activation ISTH, ‘89-91 

Chairman, Subcommittee on Contact Activation ISTH, '92-97 

Co-chairman, Subcommittee on Contact Activation ISTH, ‘98-03 

ISTH, Scientific and Standardization Committee Class of 2006 

Co-chairman, Subcommittee on Kallikrein/Kinin System ISTH, ‘05-08 

International Scientific Advisory Board of the XXII nd ISTH Congress 2009 

1989 Amer Society of Biochemistry and Molecular Biology 

1990 Elected to the American Society of Clinical Investigation 

1991 Elected to the Peripatetic Club 

The Protein Society 

1994 Central Society for Clinical Research


1997 Fellow, Council of Arteriosclerosis, Thrombosis, and Vascular 

1998 Biology, American Heart Association 

1998 Elected to the Association of American Physicians 

1998-2002 Member, Scientific Subcommittee on Clinical Laboratory Hematology 

American Society of Hematology 

2000-2002 NASCOLA (North American Specialized Coagulation Laboratory Association): 

Founding member and “At Large” member of Executive Committee 

2001-2002 Chairman, Scient. Subcommit. on Clin. Lab. Hematology, 

Amer Soc. of Hematology 

2002-2005 Hematology/Oncology Subpeciality Chairman, Central Society for Clinical 

Research 

2002-2004 Vice-President, NASCOLA 

2004-2006 Councilor, Central Society for Clinical Research 

2004-2006 President, NASCOLA 

2006-Present Immediate Past-President , NASCOLA 

2007 Association of Speciality Physicians 

2008 ASH: Teaching Cases Subcommittee of Educational Committee 

2009-Present ASH: Chairman, Teaching Cases Subcommittee of Educational Committee 

ASH: Member, Educational Committee 2010, 2011, 2012 

ASH: Research Training Award for Fellows Study Section, 2010, 2011, 2012 

TEACHING ACTIVITIES: (2005) (hours lecturing) 

Medical School: Course Director, M2 Hematology Sequence U of Michigan (Total Time=160 h) 

2/16/05: Lectured M4 Clinical Pharmacology Course: Anticoagulants (3 h) 

1/3/05: M2 Hematology Course: “Approach to Diagnosis of Anemias” (1 h) 

1/4//05 M2 Hematology Course: “Small Group-Microcytic Anemia” (2.5h) 

1/4/05: M2 Hematology Course: “Normal Blood Laboratory” (4 h) 

1/5/05: M2 Hematology Course: “Overview to Hemostasis and Thrombosis” (1 h) 

1/5/05: M2 Hematology Course: “Approach to Bleeding Patient” (1 h) 

1/6/05: M2 Hematology Course: “Approach to Thrombosis: (1 h) 

1/6/05: M2 Hematology Course: “Abnormal Blood Laboratory” (4 h) 

1/7/05: M2 Hematology Course: “Small Group-DIC” (2.5h) 

1/14/05: M2 Hematology Course: “Case Review Studies” (2 h) 

1/14/05: M2 Hematology Course: “Morphology Review” (2 h) 

(2006) (hours lecturing) 

1/5/06: M2 Hematology Course, UofM: “Overview to Hemostasis and Thrombosis” (1 h) 

1/5/06: M2 Hematology Course UofM: “Approach to Bleeding Patient” (1 h) 

1/6/06: M2 Hematology Course UofM: “Approach to Thrombosis: (1 h) 

1/6/06: M2 Hematology Course UofM: “Anticoagulants & Antiplatelet Agents”: (1 h) 

1/6/06: M2 Hematology Course UofM: “Small Group DIC” (2.5 h) 

5/5/06: M1 Hematology Course CWRU: “Approach to Thrombosis: (1 h) 

5/5/06: M1 Hematology Course CWRU: “Anticoagulants & Antiplatelet Agent”: (1 h) 

8/14/06 M3 Dept of Med Rotation: “Anemia & Coagulation Defects”: (1 h) 

8/31/06 M2 Bedside-Bench-to-Bedside talk: Thrombosis 2 nd year med students (1 h) 

9/1/06 M3 Basic science correlates: Thrombosis 3 rd year med students (1 h) 




1/15/07: Small groups3rd yr med students: Anemia & Long APTT – 1 hr 





8/22/07: Overview of Hemostasis & Approach to Bleeding Patient – 2 nd yr Med Students – 1 hr 

8/24/07: Approach to Thrombosis & Anticoagulation – 2 nd yr Med Students – 1 hr 

8/31/07: Research in Thrombosis – 2 nd yr Med Students – 1 hr 



10/19/07: Cancer Biology Group-Breast Cancer, 2 nd yr Med Students – 2 hr






8/20/08: Approach to Bleeding Patient – 1 h; 2 nd year medical school class 

8/22/08: Thrombosis – 1 h, 2 nd year medical school class 

8/22/08: anticoagulation – 1 h, 2 nd year medical school class 




1/14/09: Small group 3rd yr med students: Anemia & Long APTT – 1 hr 

8/19/09: 2 nd year medical student lecture: Overview of Hemostasis and Thrombosis and Approach to the 

Bleeding Patient – 1 hr 

8/21/09: 2 nd year medical student lecture: Approach to Thrombosis and Anticoagulation and Antiplatelet 

Agents – 2 hr 



Bleeding Patient and Platelets - 2 hr 





Bleeding Patient and Platelets - 2 hr 



Post-Graduate: (2004) 

1/20/04: PIBS” “Careers in Biotech: How to start a company” 

3/4/04: Health Service-CME: “Hypercoagulability” 

4/4/04: Clinical Pathology Grand Rounds: “Overview of Hemostasis & Thrombosis” 

4/23/04: Clinical Pathology Grand Rounds: “Approach to the Bleeding Paient” 

5/21/04: Clinical Pathology Grand Rounds: “Approach to Thrombosis” 

5/25/04: Dept of Family Practive: “Prothrombotic States” 

6/9/04: Noon Conference, Dept of IM: “Evaluation of the APTT, PT or Both” 

8/26/04: Stroke Group, UofM: “Linking Blood Pressure Control with Thrombosis” 

10/6/04: Hem/Onc Fellows: “Anticoagulation I” 

10/13/04: Noon Conference, Dept of IM: “Evaluation of Blood Coagulation Tests” 

10/15/04: PIBS: Research Area Presentation: “Kallikrein/Kinin System” 

10/29/04: Dental School: “Hemostasis Overview” 

11/3/04: Hem/Onc Fellows: “Anticoagulation II” 

11/4/04: Dental School: “Anticoagulants” 

11/23/04: Fellow’s Case Presentation, Dr. Grace Chen: “Heparin-Induced Thrombocytopenia” 

11/30/04: Michigan Business School: “LS3 Seminar-Biopure and launch of Oxyglobin” 

12/16/04: Neuro-Opthalomology Grand Rounds: “Heparin-Induced Thrombocytopenia” 

(2005) 

2/14/05: Division Fellows UofM: “How to write an R01”- 2 h seminar 

3/1/05: Cardiology Grand Rounds UofM: “Linking Blood Pressure Control with Thrombosis” 

3/22/05: Clinical Pathology Grand Rounds UofM: “HITTS and its Laboratory Assessment” 

3/29/05: Clinical Pathology Grand Rounds UofM: “The Laboratory Analysis for Lupus Anticoagulants” 

4/5/05: Clinical Pathology Grand Rounds UofM+: “Basic Assays in Clinical Coagulation Testing” 

12/16/05: M&M CWRU, ICH on heparin 

(2006) 

1/27/06: M&M CWRU, Bleeding with CAD & Waldinstrom Macroglobulinemia 

2/24/06: M&M CWRU, Hemophagocytosis Syndrome 

3/6/06: Agre Society CWRU Presentation 

4/11/06: CWRU, Department of Medicine, Medical Grand Rounds. 

“Development of a Novel Thrombin Receptor Activation Antagonist” 

5/2/06: CWRU, Department of Pharmacology, “Development of a New Class of 

Thrombin Receptor Activation Antagonists”


5/11/06: CWRU, Division of Rheumatology, “Thrombosis Disorders” 

5/23/06: CWRU, Department of Pathology, “Overview of Hemostasis & Thrombosis” 

5/24/06: CWRU, Division of Cardiology, “Interaction of the Plasma Kallikrein/Kinin system and Their 

Relation to Thrombosis Risk” 

5/30/06: CWRU, Department of Pathology, “Approach to Bleeding Patient” 

6/13/06: CWRU, Department of Pathology, “Acquired Bleeding Disorders” 

6/20/06: CWRU, Department of Pathology, “Approach to Patients with Thrombosis” 

7/7/06: CWRU, Division of Hematology/Oncology Fellows’ Conference: “Approach to Bleeding 

Patient” 

7/26/06: CWRU Division of Hematology/Oncology, Cancer Center’s Grand Rounds: “Approach to 

Thrombosis Patient” 

9/20/06: CWRU Division of Hematology/Oncology Cancer Center Grand Rounds: “Acquired Bleeding 

Disorders” 

(2007) 

3/26/07: Morning Report – Homocysteine Metabolism 

5/18/07: Dept of Medicine – M&M conference – Hemophagocytosis Syndrome 

6/4/07: Dept of Medicine – Noon conference – Cases of Bleeding States 

6/18/07: Depart of Pathology: “Novel Targets for Arterial Thrombosis in the Plasma Kallikrein/Kinin 

and Renin/Angiotension Systems.” 

7/18/07: Cancer Center Grand Rounds – “Approach to the Bleeding Patient” 

8/3/07: Fellow’s Conference – “Thrombosis” 

8/29/07: Cancer Center Grand Rounds – “Anticoagulants” 

8/31/07: M&M: “Hemophilia A, ACS, & Throat Cancer” 

12/14/07: M&M: Bleeding State on Coumadin 

(2008) 

1/23/08: CRISS Seminar: “Novel Proteins for Arterial Thrombosis Risk in the Plasma Kallikrein/Kinin 

& Renin Angiotensin Systems” 

2/15/08: M & M, AIHA in a SLE Patient 

4/3/08: Family Practice Grand Rounds: “Thrombosis” 

8/7/08: Noon Conf Dept of Medicine: Venous thrombosis 

12/12/08: M & M, Severe Evans Syndrome 

(2009) 

1/20/09: Medical Grand Rounds: “Thrombosis: Present & Future” 

5/8/09: M&M. “Parvovirus RBC aplasia in a patient with hereditary spherocytosis” 

7/18/09: Hematology Fellows Talk: “Evaluation of Anemia” – 1 hr 

8/6/09: Noon conference: “Thrombosis” – 1 hr 

8/14/09: Fellows conference-“Approach to Bleeding Patient” 

9/11/09: M&M. “Coagulopathy of Liver Disease” 

8/28/09: Fellows conference-“Approach to Thrombosis” 

(2010) 

Weekly, clinical hematology conference-patient problems – 1 h for 50 weeks/year 

8/27/10: Fellows conference-“Approach to Bleeding Patient” – 1 h 

9/3/10: Fellows conference-“Thrombosis” – 1 h 

9/22/10: Fellows conference-“Thrombocytopenia” – 1 h 

(2011) 

2/17/11: Rheumatology Grand Rounds: “Update on Thrombosis and APA Syndrome” 

2/23/11: Hem/Onc Grand Rounds: “What is beauty – from the prolylcarboxypeptidase perspective” 

3/11/11: DOM M&M – ”MAHA and TTP/HUS/aHUS” 

3/14/11: Cancer Center Chalk Talk-”Prolylcarboxypeptidase” 

7/11/11: Department of Plastic Surgery: ”Thrombosis Update, 2011” 

8/11/11: Fellows talk – ”Thrombophilia” 

8/26/11: Dom M&M – ”Thrombosis and Budd-Chiari Syndrome” 

Invited Presentations: (2003) 

1/07/03: Life Science Strategy Seminar, Business School, University of Michigan: “Corporate Strategy, 

Organization and Culture (A), Merck” 


Organization and Culture (A),Eli Lille”



Organization and Culture (A),Genzyme: Engineering the Market for Orphan Drugs” 


Organization and Culture (A), Millennium Pharmaceuticals-Growth by Mergers and Acquistions” 

6/10/03: Division of Clinical Pharmacology, Department of Internal Medicine, Vanderbilt University, 

Nashville, TN “The Plasma Kallikrein/Kinin System Interacts with the Renin Angiotensin System” 

9/24/03: Texas Club of Internists; Birmingham, MI. “Low MW Heparin: its Use and Complications” 

Management, A Double Role for the Clinical Lab” 

9/30/03: Dade Days Symposium, Ypsilante, MI. “Heparin-Induced Thrombocytopenia: Diagnosis and 

10/2/03: Lakeland Hospital, St. Josephs, MI. “New Anticoagulants and Their Use for Heparin-Induced 

Thrombocytopenia” 

(2004) 

2/13/04: American Society of Hypertension, Laragh Conference, “Interaction between the renin- 

angiotensin and plasma kallikrein/kinin systems”, Turnberry Isle Resort & Club, Aventura, FL 

9/14/04: Dade Days, Yspsilante, MI, “Monitoring Anticoagulants” 

9/21/04: Escola de Paulista de Medicina, Sao Paulo, Brazil: “Novel Intereactions Between the Plasma 

Kallikrein/Kinin and Renin-Angiotensin Systems” 

9/22-9/25/04: Brazilian Society of Clinical Pathology, Annual Meeting, Florinopolis, Brazil 

9/22/04: “Disseminated Intravascular Coagulation-An Overview” 

9/23/04: “Approach to the Patient with Thrombosis” 

9/23/04 “Novel Anti-thrombin Agents Derived from Bradykinin” 

9/23/04: “Platelet Function Testing” 

9/24/04: “Laboratory Assessment of AntiPhospholipid Syndrome” 

10/18/04: Toronto Heart Institute, Distinguished Visiting Professor, Toronto, Canada: 

“Linking Blood Pressure Control and Thrombosis: Novel Interactions between the 

Plasma Kallikrein/Kinin and Renin Angiotensin Systems” 

11/17/04: Weil Medical College, Cornell Medical Center, Hematology Conference, New York 

NY: “Linking Blood Pressure Control and Thrombosis: Novel Interactions between 

the Plasma Kallikrein/Kinin and Renin Angiotensin Systems” 

(2005) 

2/13/05: American Venous Society, San Diego, CA: “Heparin-Induced Thrombocytopenia, 

Management Decisions for the Surgeon” 

3/12/05: The Robert Rosenberg Retirement Symposium, Gates Building, MIT, Boston Mass: “Novel 

Mechanism for Thrombosis Protection: Over-Expression of the Angiotensin Receptor 2 in the 

Bradykinin B2 Receptor Knockout Mice Protests Against Thrombosis” 

4/26/05: Temple University School of Medicine, Thrombosis Center Research Conference, Philadelphia, 

PA. “Thrombostatin-An Update in its Development” 

5/20/05: Case Western Reserve University, Department of Internal Medicine, Cleveland, OH. “Linking 

Blood Pressure Regulation, Thrombosis, and Metabolic Syndrome: Revised Understanding of 

the Plasma kallikrein/kinin System” 

6/15/05: Mayo Clinic: Mayo Clinical Coagulation Conference, Rochester, MN. “NASCOLA: History of 

The Organization”. 

6/16/05: Mayo Clinic: Mayo Clinical Coagulation Conference, Rochester, MN. “Direct Thrombin 

Inhibitors-Agents and Uses”. 

8/7/05: Sydney, Australia: Kallikrein/Kinin Subcommittee of the SSC of the ISTH: “Update on 

Development of Thrombostatin” 

8/12/05: Brisbane, Australia; Queensland Technical University: “ThrombostatinTM: A Novel Thrombin 

Receptor Activation Antagonist” 

9/21/05: Bowling Green, OH, Dept. of Chemistry, Bowling Green State College: “Re-Thinking the 

Plasma Kallikrein-Kinin System: Linking Thrombosis Risk, Metabolic Syndrome, and Hypertension” 

9/23/05: Cleveland, Ohio, Dade Days. “Heparin-Induced Thrombocytopenia & Thrombosis Syndrome” 

10/14/05: Lexington, OH, U of Kentucky,Cancer Center Symposium, “Altering the Cascade: New 

Interventions in Bleeding and Thrombosis. “Thrombophilia and New Anticoagulants” 

10/21/05: Chicago, IL, University of Illinois at Chicago; Symposium for Dr. Ervin G. Erdös. 

“Prolylcarboxypeptidase and prekallikrein activation” 

10/22/05: Dearborn, MI, University of Michigan Conf. Practical Management of Venous Disease. 

“Venous Thrombosis Associated with Heparin Induced Thrombocytopenia” 

(2006) 

3/8/06: Camden, NJ, Rutgers NJ Copper Medical Center, Division of Cardiology.

Thrombosis”. 


“Prolylcarboxypeptidase: A Novel Protein Linking Hypertension, Thrombosis, and Medtabolic 

Syndrome” 

4/21/06: Cleveland, OH, CWRU, New Faculty Symposium. “Linking Blood Pressure Regulation, 

Thrombosis, and Metabolic Syndrome: Animal Models of the Plasma Kallikrein/Kinin System” 

6/29/06: Subcommittee on the Plasma Kallikrein/Kinin System, SSC of the ISTH, Oslo Norway. 

“Animal Models of the Plasma Kallikrein/Kinin System and Their Relation to Thrombosis” 

10/17/06: Teleconference, American Society of Clinical Pathology, “Newer Anticoagulant Therapies, 

Mechanisms of Action & Laboratory Monitoring” 

11/10/06: Cell Biology Department, Lerner Research Center, Cleveland Clinic Foundation, “Novel 

Target for Arterial Thrombosis” 

(2007) 

3/7/07: Metro Hospital Research Seminar Series, Cleveland, OH “Novel Target for Arterial 

3/23/07: Kellermeyer Chair Presentation: “Novel Mechanisms for Arterial Thrombosis: The Physiology 

of the Plasma Kallikrein/Kinin System”. 

4/26/07: Mayo-NASCOLA conf., Minneapolis MN “Standardization of Platelet Function Testing.” 

5/10/07: ISLH Meeting, Miami FL “Standardization of Platelet Function Testing.” 

6/1/07: Kinin 2007, Berlin, Germany “Novel Targets for Arterial Thrombosis in the Plasma 

Kallikrein/Kinin and Renin/Angiotension Systems.” 

7/7/07: SSC of the ISTH, Geneva, Switzerland “Novel Targets for Arterial Thrombosis in the Plasma 

Kallikrein/Kinin and Renin/Angiotension Systems.” 

7/7/07: SSC of the ISTH, Geneva Switzerland “Guidelines for Platelet Function Studies – CLSI 

Consensus Document” 

7/8/07: ISTH, Contact Activation Oral Sessions: “ScuPA or FXII Stimulate ERK1/2 or Akt Through 

uPAR and Beta-1-Integrins.” 

(2008) 

1/24/08: ASH 2007 Update Cleveland Clinic Cleveland, OH “Thrombosis”. 

2/27/08: Gordon Research Conference, Angiotensin: “Mechanisms for Thrombosis Protection in 

Bradykinin B2 Receptor Knockout Mice” 

3/25/08: American Society of Clinical Pathology: National Broadcast on Guidelines for the Performance 

of Platelet Function Testing. 

3/27/08: Interview by Dr. Timothy Johnson on ABC.com concerning the national heparin shortages. 

4/15/08: Vanderbilt University, Department of Clinical Pharmacology: “Influence of the plasma 

kallikrein/kinin system on vascular biology” 

5/7/08: Mini-Medical School, Case Western Reserve University, “Venous Thrombosis” 

7/2/08: Gordon Research Conference, Hemostasis, Waterville Valley, NH: “Prolylcarboxypeptidase 

knockout mice are prothrombotic and hypertensive” 

7/14/08: Association of University Technology Managers meeting, Panel discussion. “Academic’s 

Point- of-View of SBIR/STTR grants” Marriot Hotel, Cleveland, OH 

9/23/08: Sieman Days: “Venous Thrombosis, Diagnosis & Treatment”. Dublin, OH. 

(2009) 


3/12/09: Dyax, Cambridge MA. “Novel functions for plasma kallikrein” 

4/2/09: Department of Medicine Grand Rounds, MetroHealth Hospital. “Thrombosis 2009” 

7/16/09: International Thrombosis & Hemostasis Meeting, Boston, MA: Chair and Invited Speaker in 

Contact Activation Session. “Animal models of the plasma kallikrein/kinin system” 

7/29/09: Altman Hospital, Canton, OH. “Thrombosis, today & tomorrow” 

(2010) 


5/16/10: Ohio Society for Plastic Surgery: Bleeding & Clotting in the Surgical Patient 

(2011) 


6/15/11: FASEB Conf. on Proteases, Carefree AZ: Prolylcarboxypeptidase in Vascular Homeostasis 

7/23/11: ISTH SSC Meeting, Kyoto, Japan 7/24/11: Factor XII in angiogenesis and inflammation. 

7/24/11: ISTH Meeting-Symposium speaker, Kyoto, Japan 7/25/11: Thrombosis risk in the plasma 

kallikrein/kinin system. 

9/27/11: Altman Hospital, Canton OH; Thrombosis Symposium; Testing for thrombophilia and the new 

oral anticoagulants. 

10/21/11: Stroke Symposium CWRU, Management of ICH in patients on anticoagulants.


11/2/11: Arkon General Hospital-Ob symposium: Thrombois & Obstetrics and New Oral Anticoagulants 

Organized Symposium 

3/27/04: Mentoring Symposium, Biomedical Research Council, University of Michigan 

10/2/09: Symposium Honoring Oscar D. Ratnoff, Case Western Reserve University 

ATTENDING RESPONSIBILITIES: 

2001-2005: Hematology Consult Service, 1 month: University of Michigan Hospital and 

Veterans Administrative Hospital, Ann Arbor, MI 

Coagulation Laboratory Signs Outs: 1 h, twice weekly session 

Outpatient clinic: one morning weekly in hematology/oncology in the Cancer & Geriatric 

Center 

2006-2009: Hem/Onc Consult Service, 1-1.5 months/yr: University Hospital of Cleveland 

Outpatient clinic: Vascular Medicine/Hemostasis/Thrombosis Clinic: ½ day/week 

2010-2011: Hematology Consult service, 2 months/yr 

Outpatient clinic: Vascular Medicine/Hemostasis/Thrombosis Clinic: two ½ days/week 

COMMITTEE AND ADMINISTRATIVE SERVICES: 

1980-1985 Director, Hospital Coagulation Laboratory, 

Temple University Hospital, Philadelphia, PA 

1983-85 Co-Director, Hemostasis and Thrombosis Laboratory, 

Department of Medicine, Temple University Hospital 

1985-1991 Director, Hemostasis and Thrombosis Laboratories, 

Department of Medicine, Temple University Hospital 

1986 Search Committee for Pediatric Hematology/Oncology Section Head 

1986-1991 Executive Committee Thrombosis Research Center 

1990-1991 MD-PhD Program Committee, Temple University School of Medicine 

1991-2005 Director, Coagulation Laboratory, University of Michigan Hospitals 

1997-2002 Translational Research Support and Review Committee, Department of Internal 

Medicine, University of Michigan 

1999-2003 Appointments and Promotions Committee, Department of Internal Medicine, U. 

of Michigan 

2002-2004 Biomedical Research Council, University of Michigan 

2002-2005 Department of Pathology, University of Michigan Graduate Program 

2002-2003 Vice-Chair, Biomedical Research Council, U of Michigan. 

2003 Special Pharmacy Committee on Factor VIIa Usage, University of Michigan 

2003-2004 Chairman, Biomedical Research Council, U of Michigan 

3/27/04: Organized BMRC’s Mentoring Symposium 

2003-2004 Dean’s Research Advisory Board, University of Michigan, School of Medicine 

2003-2004 Special Committee Office VP Research, University of Michigan 

2004-2005 Medical School Admissions Committee, University of Michigan 

2004-2005 Office Vice President for Research University of Michigan, Faculty Grants and 

Awards Panel 

2006-Present Medical Staff: University Hospitals of Cleveland, Cleveland, OH 

2006-2007 Search Committee for Division Chief in GI, Case Western Reserve University 

2006-Present Member, Case Comprehensive Cancer Center, Case Western Reserve University 

2006-Present Co-Chair, Membership Committee, Case Comprehensive Cancer Center, CWRU 

2006-2009 Member, Department of Medicine Promotions & Tenure committee, CWRU 

2006-2009 Member, University Hospitals Case Medical Center-Cancer Center Design Team 

2006-2009 Member, Senior Leaders Committee, Case Comprehensive Cancer Center 

2007-2008 Chairman, Search Committee for Division Chief in GI, CWRU & University 

Hospitals & Case Medical Group 

2007-2009 Chairman, Search Committee for Case Comprehensive Cancer Center Associate 

Director for Clinical Research 

2007-2009 Member, Search Committee for Ireland Cancer Center, Director of Oncologic 

Programs. 

2009-Present Member CTSC Scientific Review Committee, Case Western Reserve University 

2010-Present Director, Seidman Cancer Center Clinical Laboratory


2010-Present Director, Adult Hemophilia Program 

2011-Present Director, Benign Adult Hematology Program


BIBLIOGRAPHY 

ORIGINAL PAPERS 

1. Schmaier, A.H., Maurer, H.M., Johnston, C.L. and Scott, R.B.: Alpha thalassemia screening in 

neonates by mean corpuscular volume and mean corpuscular hemoglobin determination. J. Pediat. 

83:794-797, 1973. 

2. Schmaier, A.H., Maurer, H.M., Johnston, C.L., Scott, R.B., and Stewart, L.M.: Electronically 

determined red cell indices in a predominantly black urban population of children 4 to 8 years of age. 

J. Pediat. 84:559-561, 1974. 

3. Schmaier, A.H., Claypool, W., and Colman, R.W.: Crotalocytin: recognition and purification of a 

timber rattlesnake platelet aggregating protein. Blood 56:1013-1019, 1980. 

4. Schmaier, A.H., and Colman, R.W.: Crotalocytin: characterization of the timber rattlesnake platelet 

activating protein. Blood 56:1020-1028, 1980. 

5. Schmaier, A.H., Carabello, J., Day, H.J., and Barry, W.E.: Factitious heparin administration. Ann. 

Int. Med. 96:592, 1981. 

6. Fisher, C.A., Schmaier, A.H., Addonizio, V.P., Colman, R.W.: Assay of plasma prekallikrein: 

Comparison of amidolytic esterolytic, coagulation and immunochemical assays. Blood 59:963-970, 

1982. 

7. Tuszynski, G.P., Bevacqua, S.J., Schmaier, A.H., Colman, R.W., and Walsh, P.N.: Factor XI 

antigen and activity in human platelets. Blood 59:1148-1156, 1982. 

8. Schmaier, A.H., Zuckerberg, A., Silverman, C., Kuchibhotla, J., Tuszynski, G.P. and Colman, R.W.: 

High molecular weight kininogen: A secreted platelet protein. J. Clin. Invest. 71:1477-1489, 1983. 

9. Schapira, M., Silver, L.D., Scott, C.F., Schmaier, A.H., Prograis, L.J., Curd, J.G., and Colman, 

R.W.: Prekallikrein activation and high molecular weight kininogen consumption in hereditary 

angioedema. N. Engl. J. Med. 308:1050-1053, 1983. 

10. Schmaier, A.H., and Denenberg, B.: Left ventricular thrombus with normal left ventricular function 

and hyperaggregable platelets in a patient with polycystic diseases of multiple organs. Amer. J. Med. 

Sci. 288:223-227, 1984. 

11. Schmaier, A.H., Silver, L.D., Adams, A.L., Fischer, G.L., Munoz, P.G., Vroman, L., and 

Colman, R.W.: The effect of high molecular weight kininogen on surface-adsorbed 

fibrinogen. Thromb. Res. 33:51-67, 1984. 

12. Schmaier, A.H., Gustafson, E., Idell, S., and Colman, R.W.: Plasma prekallikrein assay: Reversible 

inhibition of C1 inhibitor by chloroform and its use in measuring prekallikrein in different 

mammalian species. J. Lab. Clin. Med. 104:882-892, 1984. 

13. Schmaier, A.H., Smith, P.M., and Colman, R.W.: Platelet C1 inhibitor: A secreted alpha granule 

protein. J. Clin. Invest. 75:242-250, 1985. 

14. Switalska, H., Niewiarowski, S., Tuszynski, G.P., Rucinski, B., Schmaier, A.H., Morinelli, T.A., 

Cierniewski, C.S.: Radioimmunoassay of human platelet thrombospondin: Different patterns of 

-thromboglobulin antigen secretion and clearance from the circulation. J. 

Lab. Clin. Med. 106:690-700, 1985. 

15. Schmaier, A.H., Smith, P.M., Purdon, A.D., White, J.G., and Colman, R.W.: High molecular weight 

kininogen: Localization in the unstimulated and activated platelet and activation by a platelet 

calpain(s). Blood 67:119-130, 1986.


16. Schmaier, A.H., Bradford, H., Silver, L.D., Farber, A., Scott, C.F., Schutsky, D., and Colman, R.W.: 

High molecular weight kininogen is an inhibitor of platelet calpain. J. Clin. Invest. 77:1565-1573, 

1986. 

17. Gustafson, E.G., Schutsky, D., Knight, L., Schmaier, A.H.: High molecular weight kininogen binds 

to 

unstimulated platelets. J. Clin. Invest. 78:310-318, 1986. 

18. Schmaier, A.H., Schutsky, D., Farber, A., Silver, L.D., Bradford, H.N., and Colman, R.W.: 

Determination of the bifunctional properties of high molecular weight kininogen by studies with 

monoclonal antibodies directed to each of its chains. J. Biol. Chem. 262:1405-1411, 1987. 

19. Gluszko, P., Rucinski, B., Musial, J., Wenger, R.K., Schmaier, A.H., Colman, R.W., Edmunds, 

L.H. Jr., and Niewiarowski, S.: Fibrinogen receptors in platelet adhesion to surfaces of 

extracorporeal circuit. Amer. J. Physiol. 252:H615-H621, 1987. 

20. Cierniewski, C.S., Niewiarowski, S., Rucinski, B., Hershock, D., and Schmaier, A.H.: 

Radioimmunoassay for platelet glycoprotein IIIa. Biochem. Biophy. Acta. 924:216-224, 1987. 

21. Pixley, R.A., Schmaier, A.H., and Colman, R.W.: Effect of negatively charged surfaces on factor 

XIIa inactivation by C1 inhibitor. Arch. Biochem. Biophy. 256:490-498, 1987. 

22. Rao, A.K., Schapira, M., Clements, M.L., Niewiarowski, S., Budzynski, A.Z., Schmaier, A.H., 

Harpel, P.C., Blackwelder, W.C., Scherrer, J-R., Sobel, E., and Colman, R.W.: A prospective study 

of platelets and plasma proteolytic systems during early Rocky Mountain Spotted Fever. N. Engl. J. 

Med. 318:1021-1028, 1988. 

23. Schmaier, A.H., Farber, A.H., Schein, R., and Sprung, C.: Structural changes of plasma high 

molecular weight kininogen after in vitro activation and in sepsis. J. Lab. Clin. Med. 112:182-192, 

1988. 

24. Carvalho, A.C., DeMarinis, S., Scott, C.F., Silver, L.D., Schmaier, A.H., and Colman, R.W.: 

Activation of the contact system of plasma proteolysis in the adultrespiratory distress syndrome. J. 

Lab. Clin. Med. 112:270-277, 1988. 

25. Schmaier, A.H., Kuo, A., Lundberg, D., Murray, S., and Cines, D.B.: Expression of high molecular 

weight kininogen on human umbilical vein endothelial cells. J. Biol. Chem. 263:16327-16333, 

1988. 

26. Gustafson, E.J., Lukasiewicz, H., Wachtfogel, Y.T., Norton, K.J., Schmaier, A.H., Niewiarowski, 

S., Colman, R.W.: High molecular weight kininogen inhibits fibrinogen binding to cytoadhesins of 

neutrophils and platelets. J Cell Biology. 109:377-387, 1989. 

27. Gustafson, E.J., Schmaier, A.H., Wachtfogel, Y.T., Kaufman, N., Kucich, U., Colman, R.W. : 

Human neutrophils contain and bind high molecular weight kininogen. J Clin. Invest. 84:28-35, 

1989. 

28. Schmaier, A.H., Murray, S.C., Heda, G.D., Farber, A., Kuo. A., McCrae, K., Cines, D.B.: 

Synthesis and expression of C1 inhibitor by human umbilical vein endothelial cells. J Biol Chem. 

264: 18173-18179, 1989. 

29. Chhibber, G., Cohen, A., Lane, S., Farber, A., Meloni, F.J., Schmaier, A.H.: Immunoblotting of 

plasma in a pregnant patient with hereditary angioedema. J Lab Clin Med. 115:112-121, 1990. 

30. Schmaier, A.H., Bradford, H.N., Lundberg, D., Farber, A., Colman, R.W.: Membrane expression of 

platelet calpain. Blood. 75:1273-1281, 1990. 

31. Van Nostrand, W.E., Schmaier, A.H., Farrow, J.S., Cunningham, D.D.: Protease nexin-II(Amyloid 

-protein precursor): A platelet -granule protein. Science. 248:745-748, 1990.


32. Heda, G.D., Mardente, S., Weiner, L., Schmaier, A.H.: Gamma interferon increases in vitro and in 

vivo expression of C1 inhibitor. Blood. 75:2401-2407, 1990. 

33. Bradford, H.N., Schmaier, A.H., Colman, R.W.: Kinetics of inhibition of platelet calpain II by 

human kininogens. Biochemical Journal. 270:83-90, 1990 

34. Pasquale, L.R., Moster, M.L., Schmaier, A.H. : Dural sinus thrombosis with abnormalities of 

protein S and fibrinogen. Arch Ophthalmol. 108:644, 1990. 

35. Meloni, F.J., Schmaier, A.H. : Low molecular weight kininogen binds to platelets to modulate 

thrombin- induced platelet activation. J Biol Chem. 266:6786-6794, 1991. 

36. Van Nostrand, W.E., Schmaier, A.H., Farrow, J.S., Cines, D.B., Cunningham, D.D.: 

Protease nexin-2/amyloid -protein precursor in blood is a platelet-specific protein. Biochem 

Biophys Res Comm. 175:15-21, 1991. 

37. Kaufman, N., Page, J.D., Pixley, R.A., Schein, R., Schmaier, A.H., Colman, R.W. 2macroglobulin- 

kallikrein complexes detect contact system activation in hereditary angioedema and 

human sepsis. Blood. 77:2660-2667, 1991. 

38. Nawarawong, W., Wyshock, E., Meloni, F.J., Weitz, J., Schmaier, A.H. The rate of fibrinopeptide 

B release modulates the rate of clot formation: A study with an acquired inhibitor to fibrinopeptide 

B release. Brit J Haematol. 79:296-301, 1991. 

39. Meloni, F.J., Gustafson, E.J., Schmaier, A.H. High molecular weight kininogen binds to platelets 

by its heavy and light chains and when bound has altered susceptibility to kallikrein 

cleavage. Blood. 79:1233-1244, 1992. 

40. Jiang, Y., Muller-Esterl, W., Schmaier, A.H. Domain 3 of kininogens contains a cell binding site 

and a site that modifies thrombin activation of platelets. J. Biol. Chem. 267:3712-3717, 1992. 

41. Jiang, Y., Nawarawong, W., Meloni, F.J., Schmaier, A.H. Insights on monoclonal antibodies to 

kininogens' heavy chain which influence kininogens' binding to platelets. Thromb Haemost. 

68:143-148, 1992. 

42. Schmaier, A.H., Meloni, F.J., Nawarawong, W., Jiang, Y.P. PPACK-thrombin is a noncompetitive 

inhibitor of -thrombin binding to human platelets. Thromb Res. 67:479-489, 1992. 

43. Zini, J.M., Schmaier, A.H., Cines, D.B. Bradykinin regulates the expression of kininogen binding 

sites on endothelial cells. Blood. 81:2936-2946, 1993. 

44. Schmaier, A.H., Amenta, S., Xiong, T., Heda, G.D., Gewirtz, A.M. Expression of Platelet C1 

Inhibitor. Blood. 82:465-474, 1993. 

45. Schmaier, A.H., Dahl, L.D., Rozemuller, A.J.M., Roos, R.A.C., Wagner, S.L., Chung, R., Van 

Nostrand, W.E. Protease nexin-2/amyloid -protein precursor: A tight-binding inhibitor of 

coagulation factor IXa. J. Clin Invest. 92:2540-2545, 1993. 

46. Gluszko, P., Undas, A., Amenta, S., Szczeklik, A., Schmaier, A.H. Administration of gamma 

interferon in man decreases plasminogen activation and fibrinolysis without influencing C1 

inhibitor. J Lab Clin Med. 123:232-240, 1994. 

47. Van Nostrand, W.E., Schmaier, A.H., Neiditch, B.R., Seigel, R.S., Raschke, W.C., Sisodia, S.S., 

Wagner, S.L. Expression, purification, and characterization of the Kunitz-type protease inhibitor 

domain of the amyloid -protein precursor-like protein-2 (APLP-2). Biochem Biophys. Acta. 

1209:165-170, 1994. 

48. Hasan, A.A.K., Cines, D.B., Zhang, J., Schmaier, A.H. The C-terminus of bradykinin and Nterminus 

of the light chain of kininogens comprise an endothelial cell binding domain. J. Biol.


Chem. 269:31822-31830, 1994. 

49. Schmaier, A.H., Dahl, L.D., Hasan, A.A.K., Cines, D.B., Bauer, K.A., Van Nostrand, W.E. Factor 

IXa inhibition by protease nexin-2/amyloid -protein precursor on phospholipid vesicles and cell 

membranes. Biochemistry. 34:1171-1178, 1995. 

50. Hasan, A.A.K., Cines, D.B., Ngaiza, J.R., Jaffe, E.A., Schmaier, A.H. High molecular weight 

kininogen is exclusively membrane bound on endothelial cells to influence activation of vascular 

endothelial cells. Blood. 85:3134-3143, 1995. 

51. Herwald, H., Hasan, A.A.K., Godovac-Zimmermann, J., Schmaier, A.H., Müller-Esterl, W. 

Identification of an endothlial cell binding site on kininogens' domain D3. J. Biol. Chem. 

270:14634-14642, 1995. 

52. Freeman, K., Farrow, S., Schmaier, A.H., Freedman, R., Schork, T., Lockette, W. A genetic 

polymorphism of the alpha-2-adrenergic is associated with increased platelet aggregation, 

barorecptor sensitivity and salt excretion in normotensive men. Amer. J. of Hypertension. 

8:863-869, 1995. 

53. Hasan, A.A.K., Cines, D.B., Herwald, H., Schmaier, A.H., Müller-Esterl, W. Mapping the cell 

binding site on high molecular weight kininogen's domain 5. J. Biol. Chem. 270:19256-19261, 

1995. 

54. Hasan, A.A.K., Zhang, J., Samuel, M., Schmaier, A.H. Conformation changes in low molecular 

weight kininogen alters its ability to bind to endothelial cells. Thromb and Haemostasis. 74:1088- 

1095, 1995. 

55. Van Nostrand, W.E., Schmaier, A.H., Siegel, R.S., Wagner, S.L., Raschke, W.C. Enhanced 

plasmin inhibition by a reactive center lysine mutant of the Kunitz-type protease inhibitor domain 

of the amyloid - protein precursor. J. Biol. Chem. 270: 22827-22830, 1995. 

56. Madhi, F., Van Nostrand, W.E., Schmaier, A.H. Protease nexin-2/amyloid -protein precursor 

inhibits factor Xa in the prothrombinase complex. J. Biol. Chem. 270: 23468-23474, 1995. 

57. Heda, G.D., Kehoe, K.J., Madhi, F., Schmaier, A.H. Phosphatase 2A participates in gamma 

interferon's induced upregulation of C1 inhibitor mRNA expression. Blood. 87:2831-2838, 1996. 

58. Pipe, S., Schmaier, A.H., Nichols, W.C., Ginsburg, D., Bozynski, M.E.A., Castle, V.P. Neonatal 

purpura fulminans in association with factor V R506Q mutation. J. Pediat. 128:706-709, 1996. 

59. Chao, J., Schmaier, A.H., Chen, L.-M., Yang, Z., Chao, L. Kallistatin, a novel human tissue 

kallikrein inhibitor: levels in bodily fluids, blood cells and tissues in health and disease. J. Lab. 

Clin. Med. 127:612-620, 1996. 

60. Hasan, A.A.K., Amenta, S., Schmaier, A.H. Bradykinin and its metabolite, ARG-PRO-PRO-GLY- 

PHE, are selective inhibitors of -thrombin-induced platelet activation. Circulation. 94:517-528, 

1996. 

61. Spalding, A., Vaitkevicius, H., Scott, D., Mackenzie, S., Schmaier, A., Lockette, W. Mechanism of 

epinephrine-induced platelet aggregation. Hypertension. 31:603-607, 1998. 

62. Motta, G., Rojkjaer, R., Hasan, A.A.K., Cines, D.B., Schmaier, A.H. High molecular weight 

kininogen regulates prekallikrein assembly and activation on endothelial cells: A novel mechanism 

for contact activation. Blood. 91:516-528, 1998 

63. Gitlin, S.D., Deeb, G.M., Yann, C., Schmaier, A.H. Intraoperative monitoring of danaparoid 

sodium (Orgaran) anticoagulation during cardiovascular surgery. J of Vascular Surgery. 27:568- 

575, 1998. 

64. Hasan, A.A.K., Zisman, T., Schmaier, A.H. Identification of cytokeratin 1 as a binding protein and 

presentation receptor for kininogens on endothelial cells. Proc. Nat’l. Acad. Sci. 95:3615-3620,


1998. 

65. Musial, J., Gluszko, P., Undas, A., Mahdi, F., Kang, S., Szczeklik, A., Schmaier, A.H. 

Gamma Interferon administration to patients with atopic dermatitis inhibits fibrinolysis and elevates 

C1 inhibitor. Thrombosis Research. 89:253-261, 1998. 

66. Rojkjaer, R., Hasan, A.A.K., Motta, G., Schousboe, I., Schmaier, A.H. Factor XII does not initiate 

prekallikrein activation on endothelial cells. Thromb. Haemost. 80:74-81, 1998. 

67. Schmaier, A.H., Wahl, R., Fisher, S.J., Brenner, D. The pharmacokinetics of the kininogens. 

Thrombosis Research. 92:293-297, 1998. 

68. Rojkjaer, R., Schmaier, A.H. Activation of the plasma kallikrein/kinin system on endothelial cells. 

Proceedings Association American Physicians. 111:220-227, 1999. 

69. Shariat-Madar, Z., Mahdi, F., Schmaier, A.H. Mapping kininogens’ binding domains on 

endothelial cell cytokeratin 1. J. Biol. Chem. 274:7137-7145, 1999. 

70. Hasan, A.A.K., Rebello, S.S., Smith, E., Srikanth, S., Werns, S., Driscoll, E., Faul, J., Brenner, D., 

Normolle, D., Lucchesi, B.R., Schmaier, A.H. Thrombostatin inhibits induced canine coronary 

thrombosis. Thromb Haemost. 82:1182-1187, 1999. 

71. Boulis, N.M., Bobek, M.P., Schmaier, A.H., Hoff, J.T. Use of factor IX complex in warfarin-related 

intracranial hemorrhage. Neurosurgery. 45:1113-1118, 1999. 

72. Annich, G., White, T., Damm, D., Zhao, Y., Mahdi, F., Meinhardt, J, Rebello, S., Bartlett, R.H., 

Schmaier, A.H. Recombinant Kunitz protease inhibitory domain of the amyloid -protein precursor 

as an anticoagulant in venovenous extracorporeal circulation in rabbits. Thromb. Haemost. 

82:1474-1481, 1999. 

73. Bavikatty, N.R., Killeen, A.A., Akel, N., Normolle, D., Schmaier, A.H. Association of the 

prothrombin G20210A mutation with Factor V Leiden in a midwestern American Population. 

Amer. J. Clin. Path. 114:272-275, 2000. 

74. Mahdi, F., Rehemtulla, A., Van Nostrand, W.E., Bajaj, S.P., Schmaier, A.H. Protease nexin- 

2/amyloid -protein precursor regulates factor VIIa and the factor VIIa tissue factor complex. 

Thrombosis Research. 99:267-276, 2000. 

75. Crofford, L.J., Oates, J.C., McCune, W.J., Gupta, S., Kaplan, M.J., Catella-Lawson, F., Morrow, 

J.D., McDonagh, K.T., Schmaier, A.H. Thrombosis in patients with systemic lupus erythematosus 

and systemic sclerosis treated with specific COX-2 inhibitors. A report of three cases. Arthritis & 

Rheumatism. 43:1891-1896, 2000. 

76. Shariat-Madar, Z., Mahdi, F., Schmaier, A.H. Factor XI assembly and activation on human 

umbilical vein endothelial cells in culture. Thromb. Haemost. 85:544-551, 2001. 

77. Zhao, Y., Qui, Q., Mahdi, F., Shariat-Madar, Z., Rojkjaer, R., Schmaier, A.H. Assembly and 

activation of the HK.PK complex on endothelial cells results in bradykinin liberation and NO 

formation. Amer. J. Physiol. Hear Circ Physiol. 280:H1821-H1829, 2001. 

78. Mahdi, F., Shariat-Madar, Z., Todd III, R. F., Figueroa, C.D., Schmaier, A.H. Expression and colocalization 

of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. 

Blood. 97:2342-2350, 2001. 

79. Schmaier, A.H., Srikanth, S., Elghetany, M.T., Normolle, D., Gokhale, S., Feng, H.M., Walker, 

D.H. Hemostatic/fibrinolytic protein changes in C3H/HeN mice infected with Rickettsia conorii – 

A model for Rocky Mountain Spotted Fever. Thrombosis and Haemostasis. 86:871-879, 2001. 

80. Motta, G., Shariat-Madar, Z., Mahdi, F., Sampaio, C.A.M., Schmaier, A.H. Assembly and 

activation of high molecular weight kininogen and prekallikrein on cell matrix. Thromb. and


Haemostasis. 86:840-847, 2001. 

81. Hasan, A.A.K., Schmaier, A.H., Warnock, M., Normolle, D., Driscoll, E., Lucchesi, B.R., Werns, 

S.W. Thrombostatin inhibits cyclic flow variations in stenosed canine coronary arteries. 

Thrombosis and Haemostasis. 86:1296-1304, 2001. 

82. Hasan, A.A.K., Warnock, M., Srikanth, S., Schmaier, A.H. Developing peptide inhibitors to 

thrombin activation of platelets from bradykinin analogs. Thrombosis Research, 104:451-465, 

2001. 

83. Prieto, A.R., Ma, H., Huang, R., Khan, G., Schwartz, K.A., Hage-Korban, E.E., Schmaier, A.H., 

Hasan, A.A.K., Abela, G. S. Thrombostatin, a metabolite of bradykinin, reduces platelet activation 

in a model of arterial wall injury. Cardiovascular Research. 53:984-992, 2002. 

84. Lima, A.P.C.A., Almeida, P.C., Tersariol, I.L.S., Schmitz, V., Schmaier, A.H., Juliano, L., Hirata, 

I.Y., Muller-Esterl, W., Chagas, J.R., Scharfstein, J. Heparin sulfate modulates kinin release by 

Trypanosoma cruzi through the activity of cruzipain. J. Biol. Chem. 277:5875-5881, 2002. 

85. Mahdi, F., Shariat-Madar, Z., Figueroa, C.D., Schmaier, A.H. Factor XII interacts with the 

multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on 

endothelial cell membranes. Blood. 99:3585-3596, 2002. 

86. Shariat-Madar, Z., Mahdi, F., Schmaier, A.H. Identification and characterization of 

prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J. Biol. Chem. 277:17962- 

17969, 2002. 

87. Laudes, I.J., Chu, J.C., Srikanth, S., Huber-Lang, M., Guo, R.-F., Riedemann, N., Sarma, J.V., 

Schmaier, A.H., Ward, P.A. Anti-C5a ameliorates coagulation/fibrinolytic protein changes in a rat 

model of sepsis. Amer. J. Pathol. 160:1867-1875, 2002. 

88. Moreira, C.R., Schmaier, A.H., Mahdi, F., da Motta, G., Nader, H.B., Shariat-Madar, Z. 

Identification of prolylcarboxypeptidase as the cell matrix-associated prekallikrein 

activator. FEBS Letters. 523:167-170, 2002. 

89. Chay, C.H., Cooper, C.R., Gendernalik, J.D., Dhanasekaran, S.M., Chinnaiyan, A.M., Rubin, 

M.A., Schmaier, A.H., Pienta, K.J. A functional thrombin receptor (PAR1) is expressed on bonederived 

prostate cancer cell lines. Urology. 60:760-765, 2002. 

90. Abela, G.S., Huang. R., Ma. H., Prieto. A.R., Lei, M., Schmaier AH, Schwartz, K.A., Davis, J.M. 

Laser-light scattering (LLS), a new method for continuous monitoring of platelet activation in 

circulating fluid. J. Lab. Clin. Med. 141:50-57, 2003. 

91. Jahroudi, N., Schmaier, A., Srikanth, S., Mahdi, F., Lutka, F., Bowser, R. Von Willebrand factor 

promoter targets the expression of amyloid precursor protein to brain vascular endothelial cells of 

transgenic mice. J of Alzheimer’s Disease. 5:149-158, 2003. 

92. Krijanovski, Y., Proulle, V., Mahdi, F., Dreyfus, M., Muller-Esterl, W., Schmaier, A.H. 

Characterization of molecular defects of Fitzgerald trait and another novel high molecular weight 

kininogen deficient patient: Insights into structural requirements for kininogen expression. Blood. 

101:4430-4436, 2003. 

93. Hasan, A.A.K., Warnock, M., Nieman, M., Srikanth, S., Mahdi, F., Krishnan, R., Tulinsky, A., 

Schmaier, A.H. The mechanisms of Arg-Pro-Pro-Gly-Phe inhibition of thrombin. Amer J. Physiol 

Heart and Circ. Physiol. 285:H183-H193, 2003. 

94. Jaffa, A.A., Durazo-Arvizu, R., Zheng, D., Lackland, D.T., Srikanth, S., Garvey, W.T., Schmaier, 

A.H., and the DCCT/EDIC Study Group. Plasma prekallikrein: a risk marker for hypertension and 

nephropathy in type-1 diabetes. Diabetes. 52:1215-1221, 2003. 

95. Wang, J., Even, M.A., Chen, X., Schmaier, A.H., Waite, J.H., Chen, Z. Detection of amide I


signals of interfacial proteins in situ using SFG. J. American Chemical Society. 125:9914-9915, 

2003. 

96. Mahdi, F., Shariat-Madar, Z., Schmaier, A.H. The relative priority of prekallikrein and factors 

XI/XIa assembly on cultured endothelial cells. J. Biol. Chem. 278:43983-43990, 2003. 

97. Frick, W., Kouides, P., Kessler, C., Schmaier, A.H., Krijanovski, Y., Jagadeesan, K., Joist, J. A 

multicenterclinical evaluation of the clot signature analyzer. J. Thromb. Haemost. 2:763-768, 

2004. 

98. Mahdi, F., Shariat-Madar, Z., Kuo, A., Carinato, M., Cines, D.B., Schmaier, A.H. Mapping the 

Interaction between high molecular weight kininogen and the urokinase plasminogen activator 

receptor. J. Biol. Chem. 279:16621-16628, 2004. 

99. Shariat-Madar, Z., Mahdi, F., Schmaier, A.H. Recombinant prolylcarboxypeptidase activates 

plasma prekallikrein. Blood. 103:4554-4561, 2004. 

100. Nieman, M.T., Warnock, M., Hasan, A.A.K., Mahdi, F., Lucchesi, B.R., Brown, N.J., Murphey, 

L.J., Schmaier, A.H. The preparation and characterization of novel peptide antagonists to 

thrombin, factor VIIa and activation of protease activated receptor1. J Pharmacol Exp. Ther. 

311:492-501, 2004. 

101. Parker, A.C., Mundada, L.V., Schmaier, A.H., Fay, W.P. Factor V Leiden inhibits fibrinolysis in vivo. 

Circulation. 110:3594-3598, 2004. 

102. Nieman, M.T., Pagan-Ramos, E., Warnock, M., Krijanovski, Y., Hasan, A.A.K., Schmaier, A.H. 

Mapping the interaction of bradykinin 1-5 with the exodomain of protease activated receptor 4 

(PAR4). FEBS Lett. 579:25-29, 2005. 

103. Zhou, L., Schmaier, A.H. Platelet aggregation testing in platelet-rich plasma: description of 

procedures with the aim to develop standards in the field. Amer J. Clin. Path. 123:172-183, 2005. 

104. Shariat-Madar, Z., Rahimi, E., Mahdi, F., Schmaier, A.H. Over-expression of 

prolylcarboxypeptidase enhances plasma prekallikrein activation on Chinese hamster ovary cell. 

Am J Physiol Heart & Circ Physiol. 289:H2697- H2703, 2005. 

105. Mizrachi, I Ben-Bassat, Schmaier, A.H. , Trobe, J.D. Homonymous hemianopsia caused by 

occipital lobe infarction in heparin-induced thrombocytopenia and thrombosis syndrome. 

J. Neuroophthalmol. 25:193-197, 2005. 

106. Rectenwald, J.E., Myers, D.D., Hawley, A.E., Fex, B.A., Zajjkowski, P.J., Gangireddy, C., Longo, 

C., Henke, P.K., Guire, K.E., Schmaier, A.H., Wakefield, T.W. D-Dimer, P-Selectin, and 

Microparticles: Novel markers to predict deep venous thrombosis. Thromb. Haemost. 94:1312- 

1317, 2005. 

107. Shariat-Madar, Z., Mahdi, F., Warnock, M., Homeister, J.W., Srikanth, S., Krijanovski, Y., 

Murphey, L.J., Jaffa, A.A., Schmaier, A.H. Bradykinin B2 receptor knockout mice are protected 

from thrombosis by increased nitric oxide and prostacyclin. Blood. 108:192-199, 2006. 

Editorial Comment: Blood. 108: 1-2, 2006 

108. Burke, F.M., Warnock, M., Schmaier, A.H., Mosberg, M.I. Synthesis of novel peptide inhibitors of 

thrombin-induced platelet activation. Chemical Biology & Drug Design. 68:235-238, 2006. 

109. Chen, X., Wang, J., Paszti, Z., Wang, F., Schrauben, J.N., Tarabara, V.V., Schmaier, A.H., Chen, 

Z. 

Ordered adsorption of coagulation factor XII on negatively charged polymer surfaces by sum 

frequency generation vibrational spectroscopy. Anal Bioanal Chem. 388:65-72, 2007. 

110. Astern, J.M., Pendergraft, W.F. III, Falk, R.J., Jennetter J.C., Schmaier, A.H., Mahdi, F., Preston,


G.A. Myeloperoxidase interacts with endothelial cell-surface cytokeratin 1 and modulates the 

plasma kallikrein kininogen system. Amer J. Path. 171:349-360, 2007. 

111. Wada, M., DeLong, C.J., Hong, Y., Rieke, C.J., Song, I., Sidhu, R.S., Warnock, M., Schmaier, 

A.H., 

Yokoyama, C., Smyth, E.M., Wilson, S.J., FitzGerald, G.A., Garavito, R.M., Sui, D., Regan, J.W., 

Smith, W.L. Specificities of enzymes and receptors of prostaglandin pathways with arachidonic 

acid and eicosapentaenoic acid derived substrates and products. J Biol. Chem. 282:22254-22266, 

2007. 

112. Nieman, M.T., Schmaier, A.H. Interactions of thrombin with PAR1 and PAR4 at the thrombin 

cleavage site. Biochemistry. 46:8603-8610, 2007. 

113. Merkoulov, S., Komar, A.A., Schmaier, A.H., Barnes, E., Zhou, Y., Lu, X., Iwaki, T., Castellino, 

F.J., Lou, G., McCrae, K.R. Deletion of Murine Kininogen Gene 1 (mKng1) causes loss of plasma 

kininogen and delays thrombosis. Blood. 111:1274-1281, 2008. 

114. Nieman, M.T., Burke, F., Warnock, M., Zhou, Y., Sweigart, J., Chen, A., Ricketts, D., Lucchesi, 

B.R., Chen, Z., Di Cera, E., Hilfinger, J., Kim, J.S., Mosberg, H.I., Schmaier, A.H. Thrombostatin 

FM Compounds: direct thrombin inhibitors – mechanism of action in vitro and in vivo. J Thromb 

Haemost. 6:837-845, 2008. 

115. Xu, F., Previti, M., Nieman, M., Davis, J., Schmaier, A., Van Nostrand, W. A PP/APLP2 family 

of Kunitz serine proteinase inhibitors regulate cerebral thrombosis. J of Neuroscience. 29:5666-5670, 

2009. 

116. Wallingford, N., Perroud, B., Gao, Q., Coppola, A., Gao., X.-B., Diament, A., Haus, K.A., Shariat- 

Madar, Z., Mahdi, F., Wardlaw, S.L., Schmaier, A.H., Warden, C.H., Diano, S. 

Prolylcarboxypeptidase influences food intake by promoting breakdown of -MSH. J. Clin. Invest. 

119;2291-2302, 2009. 

Editorial Comment: J Clin Invest. 119: 2130-2133, 2009 

117. Nieman, M., LaRusch, G., Fang, C., Zhou, Y., Schmaier, A.H. Oral thrombostatin FM19 inhibits 

prostate cancer. Thromb Haemost. 2010: 104: 1044-1048. 

118. LaRusch, G.A., Mahdi, F., Shariat-Madar, Z., Adams, G., Sitrin R.G., Zhang, W.M., McCrae, 

K.R., Schmaier, A.H. Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the 

EGFR to initiate angiogenesis. Blood. 115:5111-5120, 2010. 

Editorial Comment: Blood. 115: 4979-4980, 2010 

119. Akesson, P., Herwald, H., Ramussen, M., Kakansson, K., Abrahamson, M., Hasan, A.A.K., 

Schmaier, A.H., Muller-Esterl, W., Bjorck, L. Stretococcal protein SIC: an inflammatory virulence 

determinant. Microbiology. 156:3660-3668, 2010. 

120. Adams, G.N., LaRusch, G.A., Stavrou, E., Zhou, Y., Nieman, M., Jacobs, G., Cui, Y., Lu, Y., Jain, 

M.K., Mahdi, F., Shariat-Madar, Z., Okada, Y., D’Alecy, L.G., Schmaier, A.H. Murine 

prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial 

thrombosis. Blood. 117:3929-3937, 2011. 

Editorial Comment: Blood. 117:3705-3706, 2011. 

121. Xu-Cai, Y., Shen, J., Chen, S., Zhou, Y., LaRusch, G.A., Stavrou, E., Schmaier, A., Wu, Q. Factor 

XII gene mutation in the Hageman Family. J Thromb Haemost. 9:2329-2331, 2011. 

122. Mayne, E., Funderburg, N.T., Sieg, S.F., Asaad, R., Kalinowska, M., Rodriguez, B., Schmaier, 

A.H., Stevens, W., Lederman, M.M. Increased platelet and microparticle activation in HIV 

infection: upregulation of P-selectin and tissue expression. J of AIDS. 59(4):340-346, 2012


PATENTS 

1. Colman, R.W. and Schmaier, A.H..: U.S. Patent No.:4,908,431; Antibodies to Human Kininogen 

and Methods of Preparing Same. Date of Issue 4/13/1990. 

2. Colman, R.W. and Schmaier, A.H.; U.S. Patent No.: 5,047,323; Method for Detecting Human 

Kininogen Using Monoclonal Antibodies. Date of Issue 9/10/1991. 

3. Schmaier, A.H. and Jiang, Y.P. U.S. Patent No.: 5,472,945; Modulation of Blood Pressure and 

Inhibition of Platelet Activation with Kininogen Fragment. Date of Issue 12/5/1995. 

4. Schmaier, A.H. and Hasan, A.A.K.: U.S. Patent No.: 6,143,719; Bradykinin Analogs as Selective 

Thrombin Inhibitors. Date of Issue 11/7/2000. 

5. Schmaier, A.H., and Hasan, A.A.K. U.S. Patent No.: 6,982,249 B1 Bradykinin Analogs as 

Selective Inhibitors of Cell Activation. Date of Issue 1/3/2006. 

6. Schmaier, A.H. and Hasan, A.A.K. U.S. Patent No.: 6,544,750; Peptide Analogs as Selective 

Inhibitors of Thrombin Activation of Protease Activated Receptor 1. Date of Issue 4/8/2003. 

7. Schmaier, A.H. and Hasan, A.A.K. U.S. Patent No.: 7,074,765; Synthetic Peptide Analogs of Arg- 

Pro-Pro-Gly-Phe As Selective Inhibitors of Thrombin and Thrombin Activation of Protease 

Activated Receptors 1 And 4. Filed 5/1/03, Date of Issue 7/11/2006. 

8. Schmaier, A.H., Marques, F.F., Mosberg, H.I., Hilfinger, J. U.S. Patent No.: 7,879,792 B2 

Synthetic peptide Inhibitors of Thrombin and Thrombin Activation of Protease Activated Receptors 

1 and 4. Filed 6/2/2005, Date of Issue 2/1/2011 

LETTERS TO THE EDITOR, EDITORIALS, COMMENTARIES 

1. Schmaier, A.H.: Pseudohypoxemia due to leukemia and thrombocytosis. New Engl. J. Med. 

302:584, 1980 (Letter). 

2. Schmaier, A.H. and Van Nostrand, W.E.: Alzheimer’s disease and -amyloid. New Engl. J. Med. 

326:1292, 1992 (Letter). 

3. Schmaier, A.H.: Amyloid -protein precursor: A new anticoagulant? J. Lab. Clin. Med. 130:5-7, 

1997 (Editorial). 

4. Schmaier, A.H.: Heparin versus hirudin for acute coronary syndromes. New Engl. J. Med. 

336:730, 1997 (Letter). 

5. Schmaier, A.H.: Aprotinin: can its benefit prove harmful? Transfusion. 37:1105-1107, 1997 

(Editorial). 

6. Schmaier, A.H., Rojkjaer, R. The role of factor XII in contact system activation. Blood. 92:703- 

704, 1998 (Letter). 

7. Schmaier, A.H. Disseminated intravascular coagulation. New Engl. J. Med. 341:1937-1938, 1999 

(Letter). 

8. Crofford, L.J., McDonagh, K.T., Schmaier, A.H., Oates, J.C. Cyclooxygenase 2 inhibitors and 

thrombogenicity production: comment on the article by Crofford et al. Arthritis & Rheumatism. 

44:1230, 2001 (Letter). 

9. Schmaier, A.H. The plasma kallikrein/kinin system counterbalances the renin angiotensin system. 

J. Clin. Invest. 109: 1007-1009, 2002.


10. Schmaier, A.H. The physiologic basis of assembly and activation of the plasma kallikrein/kinin 

system. Thromb. Haemost. 91:1-3, 2004. 

11. Simon, D.I., Schmaier, A.H. Sweet and sticky: diabetic platelets, enhanced reactivity, and 

cardiovascular risk. J Amer Coll Cardiol. 50:1548-1550, 2007. 

12. Schmaier, A.H., Gerson, S.L. Oscar D. Ratnoff (1916-2008). The Hematologist – American Society of 

Hematology. July-August, 2008. 

13. Schmaier, A.H. The elusive physiologic role of factor XII. J Clin Invest. 118:3006-3009, 2008. 

14. Schmaier, A.H. Response to A.P. Kaplan. Factor XII: Inflammation versus coagulation. 

http://www.jci.org/eletters/view/36617 

15. Schmaier, A.A., Schmaier, A.H. Thrombosis in flowing blood. Blood. 114:754-756, 2009. 

16. Schmaier, A.H. Why do we want to know how factor XII levels are modulated? Thrombosis Research. 

125:105-106, 2010. 

17. Schmaier, A.H. Oscar D. Ratnoff: A man for all seasons. Thromb. Haemostasis. 104: 863-866, 2010. 

18. Schmaier, A.H. Are maternal antiplatelet antibodies a prothrombotic condition leading to miscarriage? J 

Clin Invest. 121:4241-4243, 2011. 

19. Adams, G.N., Schmaier, A.H. The Williams-Beuren syndrome – A window into genetic variants leading 

to the development of cardiovascular disease. Plos Genetics. 2012;8(2) e1002479 (February, 2012). 

JOURNAL THEME ISSUE: 

1. Schmaier, A.H. Theme Issue Ratnoff Symposium 2009. Thromb Haemostasis. 104:863-1082, 2010. 

BOOKS 

1. Schmaier, A.H., Petruzzelli, L.M. (eds). Hematology for Medical Students. Lippincott, Williams & 

Wilkins, Baltimore, 2003. 

2. Schmaier, A.H., Lazarus, H. (eds). Concise Guide to Hematology. Wiley-Blackwell, Oxford, 2012. 

REVIEW ARTICLES AND BOOK CHAPTERS 

1. Colman, R.W., Schmaier, A.H. and Wong, P.: The kallikrein-kinin system. In: Biochemical 

Regulation of Blood Pressure. R.L. Soffer (Ed.) John Wiley and Sons, New York, 1981, pp. 321- 

355. 

2. Schmaier, A.H. ,and Colman, R.W.: Disseminated intravascular coagulation: An approach to 

management including the use of blood component therapy. In: Standardization of Coagulation 

Assays. D.A. Triplett, , R. Wertz, M. O'Sullivan, G. Penn, and J. Koepke, (Eds.) College of 

American Pathologists, Skokie, IL, 1982, pp. 353-367. 

3. Schmaier, .A.H., and Day, H.J.: A classification of disorders of hemostasis and thrombosis in 

patients with maligancy. In: Interaction of Platelets and Tumor 

Cells. G.V. Jamison (Ed.) Alan Liss, Inc., New York, 1982, pp. 1-20. 

4. Rao, A.K., Schmaier, A.H., and Colman, R.W.: Plasma coagulation proteases, proteolytic 

inhibitors and their interaction with platelets. In: Pathobiology

1987. 


Annual. H.L. Ioachim (Ed.) Raven Press, New York, 12:35-64, 1982. 

5. Schmaier, A.H., Schapira, M., and Colman, R.W.: Methodology to study the proteins of contact 

phase of coagulation. In: Disorders of Thrombin Formation. R.W. Colman (Ed.) Churchill 

Livingston, Inc., New York, 1983, pp. 24-77. 

6. Schmaier, A.H., and Colman, R.W.: Current therapeutic approach in the management of 

disseminated intravascular coagulation. In: Current Therapy in Hematology/Oncology. M.C. 

Brain (Ed.); B.C. Decker, Inc., 1983, p. 164-169. 

7. Schmaier, A.H.: Oncologic Emergencies. Resident and Staff Physician. 29:63-76, 1983. 

8. Schmaier, A.H.: Disseminated intravascular coagulation and activated coagulation: Laboratory 

methods for diagnosis and a guide to therapy. In: Laboratory Hematology. J. Koepke (Ed.) 

Churchill Livingston, Inc., New York, 1984, pp. 631-658. 

9. Schmaier, A.H., and Colman, R.W.: Disseminated intravascular coagulation. In: Current Therapy 

in Internal Medicine 1984-1985. T.H. Baylen, M.C. Brain, R.M. Chernack (Eds.) B.C. Decker, 

Inc., 1984, Philadelphia, pp. 325-329. 

10. Schmaier, A.H., and Colman, R.W.: Hemorrhagic disease due to disseminated intravascular 

coagulation and fibrinolysis. In: Current Diagnosis. R.B. Conn (Ed.) W.B. Saunders, Co., 

Philadelphia, 1985, pp. 624-628. 

11. Schmaier, A.H., and Colman, R.W.: Hemorrhagic disease due to circulatory 

anticoagulants. In: Current Diagnosis. R.B. Conn (Ed.) W.B. Saunders, Co., Philadelphia, 1985, 

pp. 628-631. 

12. Schmaier, A.H., and Colman, R.W.: The contact phase of coagulation: A review and specific 

technique to study its components. In: Blood Coagulation and Haemostasis: A Practical Guide. 

J.M. Thompson (Ed.) 3rd Edition, Churchill Livingston, 1985, pp. 22-55. 

13. Schmaier, A.H.: Platelet forms of plasma proteins. P. Schick, and H. Stormorken, (Eds.) Seminars 

in Hematology, 22:187-202, 1985. 

14. Schmaier, A.H., and Colman, R.W.: The contact activation system: Biochemistry and interactions 

of these surface mediated-defense reactions. CRC Press 5:57-85, 1986. 

15. Walsh, P.N., and Schmaier, A.H.: Platelet-coagulant protein interactions. In: Hemostasis and 

Thrombosis. Colman, R.W. (Ed.), 2nd Edition, Lippincott, 1987, pp. 689-709. 

16. Schmaier, A.H., Colman, R.W., Silverberg, M., and Kaplan, A.P.: The contact activation system: 

Surface mediated defense reactions. In: Hemostasis, R.W. Colman (Ed.) 2nd Edition, Lippincott, 

1987, pp. 18-36. 

17. Schmaier, A.H.: Immunochemical methods to study platelet-associated proteins. In: Methods of 

Pharmacology, Volume 4, R.W. Colman, and J.B. Smith (Eds.) Alan R. Liss, Inc., 1987, pp. 109- 

131. 

18. Colman, R.W., Scott, C.F., Schmaier, A.H., Wachtfogel, Y.T., Pixley, R.A., and Edmunds, L.H.: 

Initiation of blood coagulation at artificial surfaces. Ann. N.Y. Acad. Sci. 516:253-267, 

19. Schmaier, A.H., and Colman, R.W.: Platelet high molecular weight kininogen: Identification and 

mechanisms of availability. In: Platelets, Receptors, Adhesion, Secretion, Part A J. Hawiger, (Ed.) 

Meth. Enzymol. 169:276-296, 1989. 

20. Schmaier, A.H.: Disseminated Intravascular Coagulation and Activated Coagulation. In: Practical 

Laboratory Hematology, 2nd Edition, J Koepke (Ed), Churchill Livingston, Inc., New York, pp 469- 

485, 1991.


21. Schmaier, A.H. : Disseminate intravascular coagulation - pathogenesis and management. J of 

Intensive Care Medicine. 6:209-228, 1991. 

22. Van Nostrand, W.E., Schmaier, A.H., Farrow, J.S., Cunningham, D.D.: Platelet 

protease nexin-2/amyloid -protein precursor. Possible pathologic and physiologic function. Ann 

N.Y. Acad. Sci. 640:140-144, 1991. 

23. Schmaier, A.H.: Modulation of the cell-membrane expression of the kininogens regulates the rate of 

bradykinin delivery to cells. Trends in Cardiovascular Medicine. 2:108-114, 1992. 

24. Schmaier, A.H. : Contact Activation. In: Thrombosis and Hemorrhage, 1st Edition, A.I. Schafer 

and J. Loscalzo (Eds), Blackwell Scientific Publications, Inc. Cambridge, MA., 1994, pp. 87-105. 

25. Jiang, Y.P. and Schmaier, A.H. : Characterization of Cell Binding and Thrombin Inhibitory 

Regions on Kininogens' Heavy Chain. In: Recent Progress on Kinins; Biochemistry and Molecular 

Biology of the Kallikrein-Kinin System. H. Fritz, M. Jochum, W. Muller-Esterl, and A. Roschler 

(Eds), Agents and Actions Supplements, Birkhauser Verlag, Basal 38/I:233-240, 1992. 

26. Van Nostrand, W.E., Schmaier, A.H., Wagner, S.L. Potential role of protease nexin- - 

protein precursor as a cerebral anticoagulant. Annals of New York Academy of Science. 674:243- 

252, 1993. 

27. Schmaier, A.H. Kininogens - gene expression, regulation, cell surface presentation. In: 

Handbook of Immunopharmacology, The Kinin System. Ed: Farmer S.G., Academic Press, 

London, United Kingdom, 1997, pp 57-70. 

28. Schmaier, A.H. Thrombin Inhibitors. In: Protease Inhibitors, Novel Therapeutic, Applications, 

and Development. Ed: Macready N. IBC Business Communications, Inc., Southborough MA, 

1997, pp.3.4.1-19. 

29. Schmaier, A.H. Contact Activation - A Revision. Ed: G. de Gaetano. In 1997 State of the Art, 

Thrombosis and Haemostasis, 78:101-105, 1997. 

30. Colman, R.W. and Schmaier, A.H. Contact system: A vascular biology modulator with 

anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood. 90:3819-3843, 

1997. 

31. Schmaier, A.H. Contact Activation. In: Thrombosis and Hemorrhage. Ed: Loscalzo J. and Schafer 

A.I. Second Edition. Williams & Wilkins, Baltimore, 1998, pp 105-127. 

32. Schmaier, A.H. Plasma contact activation - A revised hypothesis. In: Biological Research, A 

festschrift in honour of Professor Hector R. Croxatto, Eds. McGiff JC and Vio CP. 31:251-262, 

1998. 

33. Schmaier, A.H. Plasma kallikrein/kinin system: A newly recognized mechanism for its physiologic 

activation. Thrombose. 2:3-8, 1998. 

34. Wakefield, T.W. and Schmaier, A.H. Vascular thrombosis due to hypercoagulable states. In: 

Vascular Surgery. Ed: Rutherford, R.B., et al. W.B. Saunders Co, Philadelphia, 1999, pp.726-732. 

35. Wakefield, T.W. and Schmaier, A.H. Hematologic factors in recurrent venous thrombosis. In: 

Practical Vascular Surgery, Eds: Yao, J. S.T., Pearce, W.H. Appleton & Lange, 1998, pp 447-454. 

36. Wakefield, T.W. and Schmaier, A.H. Prothrombotic states and vascular thrombosis. In: Current 

Therapy in Vascular Surgery, Eds Ernst, C.B. and Stanley, J.C. 4 th Edition, Mosby, St. Louis, 2001, 

pp 543-545. 

37. Wakefield, T.W. and Schmaier, A.H. Warfarin-induced skin necrosis. In: Current Therapy in 

Vascular Surgery, Eds Ernst, C.B. and Stanley, J.C. 4 th Edition, Mosby, St. Louis, 2001, pp 860- 

861.


38. Rojkjaer, R. and Schmaier, A.H. Activation if the plasma kallikrein/kinin system on endothelial 

cell membranes. Immunopharmacology. 43:109-114, 1999. 

39. Schmaier, A.H. Inhibitors of thrombin and factor Xa. In: Handbook of Experimental 

Pharmacology, Eds: Von der Helm K, Korant BD, and Cheronis JC. Springer, Berlin, 2000, pp 

277-299. 

40. Schmaier, A.H. Acquired disorders of blood coagulation. In: Kelley’s textbook of Internal 

Medicine. 4 th Edition. Ed: Humes, H. David. Lippincott Williams & Wilkins. Philadelphia, 2000, 

pp. 1718-1723. 

41. Schmaier, A.H., Rojkjaer, R., Shariat-Madar, Z. Activation of the plasma kallikrein/kinin system 

on cells - A revised hypothesis. In: State-of-the-Art, 1999, Ed. Hoyer, L. Thromb. Haemost. 

82:226-233, 1999. 

42. Shariat-Madar, Z., Schmaier, A.H. Kininogen-cytokeratin 1 interactions in endothelial cell biology. 

Trends in Cardiovascular Medicine, 9:238-244, 1999. 

43. Schmaier, A.H. The plasma kallikrein/kinin system: a revised hypothesis for its activation and its 

physiologic contributions. In: Current Opinion in Hematology. Eds Broze, George J., Stossel, T. 

7:261-265, 2000. 

44. Schmaier, A.H. What To Do If Your NIH Application Is Not Funded? How To Take Criticism 

Constructively. Hematology 1999, American Society of Hematology Educational Program Book. 

American Society of Hematology, December, 1999. 

45. Schmaier, A.H. Disseminated Intravascular Coagulation (DIC), Adult. In: emedicine: Emergency 

Medicine, Ob/Gyn, Psychiatry, and Surgery/Hematology, Ed: Phatak PD, Talavera F, Sacher RA, 

McKenna R, Besa EC. Available at: www.emedicine.com, 2001. 

46. Schmaier, A.H. Contributions of the plasma kallikrein/kinin system to disseminated intravascular 

coagulation. In: Disseminated Intravascular Coagulation, Eds. Ten Cate H, Levi M. Landes 

Bioscience. Georgetown, TX, 2003, pp.110-117. 

47. Schmaier, A.H., Petruzzelli, L.M. Introduction to hematology. In:Hematology for the Medical 

Student. Schmaier, A.H., Petruzzelli, L.M. (eds). Lippincott, Williams & Wilkins, Baltimore, 

2003, pp 1-4. 

48. Schmaier, A.H. Principles of Hemostasis. In:Hematology for the Medical Student. Schmaier, A.H., 

Petruzzelli, L.M. (eds). Lippincott, Williams & Wilkins, Baltimore, 2003, pp. 71-77. 

49. Schmaier, A.H. Approach to the bleeding patient. In:Hematology for the Medical Student. 

Schmaier, A.H., Petruzzelli, L.M. (eds). Lippincott, Williams & Wilkins, Baltimore, 2003, pp. 79- 

83. 

50. Schmaier, A.H. Acquired bleeding disorders. In:Hematology for the Medical Student. Schmaier, 

A.H., Petruzzelli, L.M. (eds). Lippincott, Williams & Wilkins, Baltimore, 2003, pp. 99-104. 

51. Schmaier, A.H. Evaluation of thrombosis. In:Hematology for the Medical Student. Schmaier, 

A.H., Petruzzelli, L.M. (eds). Lippincott, Williams & Wilkins, Baltimore, 2003, pp. 121-126. 

52. Bockenstedt, P., Schmaier, A.H. Platelet function and disorders. In:Hematology for the Medical 

Student. Schmaier, A.H., Petruzzelli, L.M. (eds). Lippincott, Williams & Wilkins, Baltimore, 

2003, pp. 105-120. 

53. Shariat-Madar, Z., Schmaier, A.H. Assembly and activation of the plasma kallikrein/kinin system: 

A new interpretation. International Immunopharmacology. 2:1841-1849, 2002.


54. Schmaier, A.H. The NIH grant review process and what to do if your grant is not funded. 

Hematology 2002. The American Society of Hematology Education Book, December 2002. 

55. Schmaier, A.H., Finn,W.G., Petruzzelli, L.M. Atlas images. In: Hematology for the Medical 

Student. Schmaier, A.H., Petruzzelli, L.M. (eds). Lippincott, Williams & Wilkins. Baltimore, 

2003, pp Appendix 1-12. 

56. Schmaier, A.H. The kallikrein/kinin and the renin angiotensin systems have a multi-layered 

interaction. Amer. J. Physiol: Regulatory, Integrative and Comparative Physiology. 285:R1-R13, 

2003. 

57. Shariat-Madar, Z., Schmaier, A.H. The plasma kallikrein/kinin and renin angiotensin 

systems in blood pressure regulation in sepsis. J. of Endotoxin Research. 10:3-13, 2004. 

58. Schmaier, A.H. Plasma Kallikrein. XPharm Handbook in Pharmacology, Ed: Boison, D., Elsevier 

Science, Inc., 2004. 

59. Schmaier, A.H. Coagulation Factor XII. XPharm Handbook in Pharmacology, Ed: Boison, D., 

Elsevier Science, Inc., 2004. 

60. Schmaier, A.H. Introduction to Coagulation Factors. XPharm Handbook in Pharmacology, Ed: 

Boison, D. Elsevier Science, Inc., 2004. 

61. Henke, P.K., Wakefield, T.W., Schmaier, A.H. Thrombosis due to hypercoagulable states. In: 

Rutherford’s Vascular Surgery. 6 th Edition. Elsevier Science, Inc., Philadelphia, pp568-578, 2005. 

62. Schmaier, A.H. Abnormalities in Coagulation. In: Complications in Surgery. Eds: Mulholland 

M., Doherty, G. Lippincott Williams & Wilkins, Philadelphia, 2006. pp.185-194 

63. Schmaier, A.H., Thornburg, C., Pipe, S. Coagulation and Fibrinolysis. In: Henry’s Clinical 

Diagnosis and Management by Laboratory Methods. Eds: McPherson, Pincus. 21 st Edition. 

Elsevier. Philadelphia. 2007. pp. 729-745. 

64. Schmaier, A.H. Laboratory evaluation of hemostatic and thrombotic disorders. In: Hematology, 

Basic Principles and Practice, 5 th Edition. Eds: Hoffman R, Benz EJ, Furie B, Shattil SJ, Silberstein 

LE, McGlave P, Heslop HE, Anastasi J. Churchill Livingston Elsevier, Philadelphia, 2009. 

Chapter 122. pp 1877-1884. 

65. van Heeckeren W.J., Narayan, A., Sanborn, S., Cooney, M., McCrae, K., Schmaier, A.H., Remick, 

S. Complications from vascular-disrupting agents and angiogenesis inhibitors: aberrant control of 

hemostasis and thrombosis. Curr Opin Hematology. 14:468-480, 2007. 

66. Schmaier, A.H. Assembly, activation, and physiologic influence of the plasma kallikrein/kinin 

system. International Immunopharmacology. 8:161-165, 2007. 

67. Schmaier, A.H., McCrae, K.R. The plasma kallikrein/kinin system: its evolution from contact 

activation. J. Thromb Haemost. 5:2323-2329, 2007. 

68. Petrolla, A., Lazarus, H.M., Schmaier, A.H. Unique thrombotic and hemostatic complications 

associated with stem cell transplantation. In: Allogenic Stem Cell Transplantation. Eds: Lazarus, 

H., Laughlin, M. 2 nd Edition. The Humana Press, Inc. 2010, pp.695-715. 

69. Schmaier, A.H. Standardization of light transmission platelet aggregation studies in the clinical 

laboratory. International Review of Thrombosis. 2:39-47, 2007. 

70. Choi, C.M., Schmaier, A.H., Snell, M.R., Lazarus, H.M. Thrombotic microangiopathy in bone 

marrow transplantation: diagnosis and treatment. DRUGS. 69:183-198, 2009 

71. Christie, D.J., Carrington, L.R., Harrison, P., Kickler, T.S., Kottke-Marchant, K., Ledford-


Kraemer, M., Schmaier, A.H., White, M.M. Platelet function testing by aggregometry: approved 

guideline. Clinical and Laboratory Standards Institute. H58-A, Vol 28 No. 31. December, 2008. 

72. Schmaier, A.H. Abnormalities in Coagulation. In: Complications in Surgery. 2 nd Edition. Eds: 

Mulholland M., Doherty, G. Lippincott Williams & Wilkins, Philadelphia, 2011, In Press. 

73. Stavrous E., Schmaier, A.H. Factor XII: What does its contribute to our understanding of the 

physiology and pathophysiology of hemostasis & thrombosis. Thrombosis Research. 125:210-215, 

2010. 

74. Schmaier, A.H., Miller, J.L. Coagulation and Fibrinolysis. In: Henry’s Clinical Diagnosis and 

Management by Laboratory Methods. Eds: McPherson, Pincus. 22 nd Edition. Elsevier. 

Philadelphia. pp 785-800. 2011. 

75. Schmaier, A.H., LaRusch, G. Factor XII: new life for an old protein. Thromb Haemost. Theme 

Issue, 104: 915-918, 2010. 

76. Schmaier, A.H. Introduction. In: Schmaier, A.H., Lazarus, H. (eds). Concise Guide to Hematology. 

Wiley-Blackwell, Oxford, 2012, pp 1-5. 

77. Schmaier, A.H. Overview of Hemostasis & Thrombosis. In: Schmaier, A.H., Lazarus, H. (eds). Concise 

Guide to Hematology. Wiley-Blackwell, Oxford, 2012, pp91-102. 

78. Schmaier, A.H. Approach to Bleeding Patient. In: Schmaier, A.H., Lazarus, H. (eds). Concise Guide to 

Hematology. Wiley-Blackwell, Oxford, 2012, pp 103-111. 

79. Schmaier, A.H. Thrombosis and anticoagulation. In: Schmaier, A.H., Lazarus, H. (eds). Concise Guide 

to Hematology. Wiley-Blackwell, Oxford, 2012, pp 174-183. 

80. Schmaier, A.H., Petruzzelli, L.M., Borregaard, N., Boxer, L.A. Myeloid cells physiology and disorders. 

In: Schmaier, A.H., Lazarus, H. (eds). Concise Guide to Hematology. Wiley-Blackwell, Oxford, 2012, pp 

184-196. 

81. Schmaier, A.H. Atlas of hematology slides. In: Schmaier, A.H., Lazarus, H. (eds). Concise Guide to 

Hematology. Wiley-Blackwell, Oxford, 2012, pp 363-387. 

82. Schmaier, A.H. Laboratory evaluation of hemostatic and thrombotic disorders. In: Hematology, Basic 

Principles and Practice, 6 th Edition. Eds: Hoffman R, Benz EJ, Weitz, J, Shattil SJ, Silberstein LE, McGlave 

P, Heslop HE, Anastasi J. Churchill Livingston Elsevier, Philadelphia, 2013. 

83. Schmaier, A.H. Warfarin-induced skin necrosis. In: Current Therapy in Vascular and Endovascular 

Surgery. 5 th Edition. Eds: James C. Stanley, Thomas W. Wakefield, Frank J. Veith. Elsevier, Philadelphia, 

2012, In Press. 

84. Schmaier, A.H. Factor XII, factor XI, prekallikrein, and high molecular weight kininogen. In: Clinical 

Decision Support: LAB MEDICINE. 1 st edition. Eds: Laposata, Melanson, Alter. 2012, In Press. 

85. Stavrous, E., Schmaier, A.H. Factor XII Deficiency (Hageman factor deficiency). In: Handbook of 

Hemostasis and Thrombosis: Practical Guidelines in Clinical Management. Eds: Saba HI. Roberts H. 2012, 

In Press. 

86. Schmaier, A.H. Coagulation factor XIIa. In: Handbook of Pharmacology. Eds: Rawlings, N., Salvesen , 

G. Elsevier Ltd. Oxford. 2012. 

87. Schmaier, A.H. Prekallikrein and Plasma Kallikrein. In: Handbook of Pharmacology. Eds: Rawlings, N., 

Salvesen , G. Elsevier Ltd. Oxford. 2012. 

88. Arfons, L. Schmaier, A. Surgical bleeding, American Society of Hematology, Teaching Cases Website, 

http://teachingcases.hematology.org/Arfons/index.cfm.

CURRICULUM VITAE 27 Alvin H. Schmaier


ABSTRACTS 

1. Schmaier, A.H., Maurer, H.M., Johnston, C.L., and Scott, R.B.: Screening test for Hgb Barts in the 

newborn. American Society of Hematology. Hollywood, FL, December, 1972. 

2. Schmaier, A.H., Maurer, H.M., Johnston, C.L., and Scott, R.B.: Screening test for alphathalassemia 

in the newborns. Ped. Research 7:360/132, 1973. 

3. Schmaier, A.H., Maurer, H.M., Johnston, C.L., Scott, R.B., Stewart, L.M. and Laupus, W.E.: 

Hematology screening by Coulter S and hemoglobin electrophoresis. Amer. J. Clin. Path. 62:301, 

1974.* 

4. Claypool, W., Schmaier, A.H., Guerry, D. and Colman, R.W.: Timber rattlesnake venom induces 

platelet aggregation and secretion. Clin. Res. 26:344A, 1978. 

5. Schmaier, A.H., Colman, R.W., and Claypool, W.: Purification of timber rattlesnake platelet 

aggregating protein. Circ. 58:II-215, 1978.* 

6. Tuszynski, G.P., Bevacquae, S.J., Schmaier, A.H., Colman, R.W. and Walsh,P.N.: Identification of 

factor XI in human platelets. Fed. Proceed. 39:871, 1980. 

7. Schmaier, A.H., Tuszynski, G.P., Walsh,P.N., and Colman, R.W.: Immunologic identification of 

human platelet kininogen. Clin. Res. 28:323A, 1980.* 

8. Schmaier, A.H., Colman, R.W., Adams, A.L., Fischer, G.C., Munz, P.C. and Vroman, L.: 

Interaction of fibrinogen and high molecular weight kininogen on artificial surfaces. Circ. 62:III- 

57, 1980.* 

9. Schmaier, A.H., Kuchibhotla, J., and Colman, R.W.: Human platelet HMW kininogen - a secreted 

platelet protein. Thrombos. Haemostas. 46:96, 1981.* 

10. Schmaier, A.H., Kuchibhotla, J., and Colman, R.W.: Immunologic identification of platelet C1 

inhibitor. Blood 58 (Suppl): 205A, 1981. 

11. Schmaier, A.H., Fisher, C.F., Addonizio, V.A., and Colman, R.W.: Assay of 

prekallikrein in human plasma: Lack of correlation of coagulation assay with esterolytic, 

amidolytic and immunochemical assays. Clin. Res. 30:561A, 1982.* 

12. Rao, A.K., Schapira, M. Niewiarowski, S., Budzynski, A.Z., Schmaier, A.H., Mills, D., 

Willis, J., Beckett, C., James, A., Silver, L., Scott, C., James, P., Harris, M., Kieve, C., Clements, 

M.L., Levine, M., Hughes, T., Black, R., and Colman, R.W.: Prospective study of hemostatic 

systems during mild Rocky Mountain Spotted Fever. Clin. Res.30:328A, 1982. 

13. Schmaier, A.H., Zuckerberg, A., Silverman, C., Daniel, J., and Colman, R.W.: A sensitive 

competitive enzyme-linked immunoadsorbent assay to measure platelet 

high molecular weight kininogen. Circ. 66:II-296, 1982.* 

14. Schmaier, A.H., Silverman, C., Wadsworth, S., and Colman, R.W.: C1 inhibitor in human 

platelets. Clin. Res. 31:536A, 1983. 

15. Schmaier, A.H., Wadsworth, S., Smith, P., and Colman, R.W.: Identification and subcellular 

localization of platelet C1 inhibitor. Blood 62:268A, 1983. 

16. Schmaier, A.H., and Colman, R.W.: Platelet C1 inhibitor subcellular localization and secretion. 

Clin. Res. 32:322A, 1984.* 

17. Carvalho, A.C., Bellman, S., Koch, S., Schmaier, A.H., Silver, L., and Colman, R.W.: Contact 

activation of blood coagulation in acute respiratory failure. Blood 62:273A, 1983.


18. Schmaier, A.H., Smith, P., and Colman, R.W.: High molecular weight kininogen: Localization in 

unstimulated and activated platelets and activation by a platelet cysteine protease. Circ. 70:II-352, 

1984.* 

19. Gustafson, E.G., Schutsky, D., Schmaier, A.H.: High molecular weight kininogen binds to 

unactivated platelets. Clin. Res. 33:341A, 1985.* 

20. Cierniewski, C.S., Niewiarowski, S., Hershock, D., and Schmaier, A.H., : Quantification of 

glycoprotein IIIa in human blood platelets by radioimmunoassay. Thromb. Haemost. 54:69, 1985. 

21. Switalska, H.I., Niewiarowski, S., Tuszynski, G.P., Rucinski, B., Schmaier, A.H., Morinelli, T.A., 

and Cierniewski, C.S.: Use of thrombospondin to evaluate platelet 

activation in vivo. Thromb. Haemost. 54:218, 1985. 

22. Schmaier, A.H., Bradford, H., Silver, L., Schutsky, D, Farber, A., Scott, C.F., and Colman, R.W.: 

High molecular weight kininogen inhibits platelet calpain. Blood 66 (Suppl):313A, 1985.* 

23. Gluszko, P., Rucinski, B., Musial, J., Schmaier, A.H., Stewart, G.J., Edmunds, L.H.,and 

Niewiarowski, S.: 

Role of fibrinogen receptors and glycoprotein IIb/IIIa (GPIIb/IIIa) complex in platelet interaction 

with silicone rubber surfaces of stimulated extracorporeal circuit. Blood 66 (Suppl):305A, 1985.* 

24. Gustafson, E.G., and Schmaier, A.H.: High molecular weight kininogen has two platelet binding 

sites. Clin. Res. 34:459A, 1986.* 

25. Schmaier, A.H., Farber, A., Schutsky, D, Gustafson, E.G., Silver, L., and Colman, R.W.: 

Influence of monoclonal antibodies on the interaction of plasma high molecular weight kininogen 

with surfaces and platelets. Clin. Res. 34:470A, 1986.* 

26. Pixley, R.A., Schmaier, A.H., and Colman, R.W.: The effect of factor XII activating compounds on 

factor XIIa and XIIf inhibition by C1 inhibitor. Fed. Proc. 45:1638, 

1986. 

27. Gustafson, E.G., and Schmaier, A.H., and Colman, R.W.: High molecular weight kininogen binds 

to neutrophils. Blood 68:84A, 1986.* 

28. Schmaier, A.H., Farber, A., Lundberg, D, Defeo, P., and Stewart, G.: C1 inhibitor: 

Characterization of its plasma membrane expression on activated platelets. Clin. 

Res. 35:432A, 1987.* 

29. Schmaier, A.H., Kuo, A., and Cines, D.: High molecular weight kininogen expression on human 

endothelial cells. Clin. Res. 35:432A, 1987.* 

30. Gustafson, E.G., Lukasiewicz, H., Schmaier, A.H., Niewiarowski, S., and Colman, R.W.: 

Fibrinogen binds to human neutrophils at a site distinct from GPIIb/IIIa. Clin. Res. 35:598A, 

1987.* 

31. Schmaier, A.H., Farber, A., Lundberg, D, Kuo, A., Murray, S., and Cines, D.: C1 inhibitor is 

associated with endothelial cells. Blood (Suppl) 70:407A, 1987.* 

32. Schmaier, A.H., Farber, A.,Bradford, H., and Colman, R.W.: Membrane expression of platelet 

calpain. Blood (Suppl) 70:361A, 1987.* 

33. Schmaier, A.H., and Farber, A.: Structural changes of plasma high molecular weight kininogen 

after in vitro activation and in sepsis. Clin. Res. 36:418A, 1988. 

34. Meloni, F.J. and Schmaier, A.H.: Low molecular weight kininogen's binding to platelets inhibits


platelet activation. Circ (Suppl II), 78:II-545, 1988.* 

35. Bradford, H.N., Lundberg, D., Adam, A., Schmaier A.H., Colman, R.W. : Inhibition of calpain by 

kininogens: kinetics and responsible domains. Circ.(Suppl II), 78:II-545, 1988.* 

36. Schmaier,A.H., Chhibber, G., Cohen, A., Lane, S., Farber, A., Lundberg, D.: Immunoblotting of 

plasma as a single, objective assay for diagnosis of attacks of hereditary angioedema. Blood (Suppl 

1) 72:309a, 1988.* 

37. Heda, G.D., Weiner, L., Yeh, J., Schmaier, A.H.. Gamma interferon increases C1 inhibitor levels 

in vitro and in vivo. Clin Res. 37:381A, 1989.* 

38. Meloni, F.J. and Schmaier, A.H. The physiologic significance of the platelet membrane expression 

of the kininogens. Blood 74(Suppl 1):286a, 1989.* 

39. Kaufman, N., Page, J., Pixley, R.A., Schmaier, A., Schein, R., Colman, R.W. Alpha-2macroglobulin 

( 2M)-kallikrein (KAL) complex - a marker of septicemic hypotension. Clin 

Res. 38:269A, 1990.* 

40. Heda, G.D. and Schmaier, A.H. Regulation of C1 inhibitor in HEP G2 cells. FASEB J. 4:A1901, 

1990.* 

41. Meloni, F.J. and Schmaier, A.H. Plasma kininogens inhibit thrombin binding to 

and activation of platelets. Circ. 82:III-597, 1990.* 

42. Jiang, Y.P., Schmaier, A.H. Kininogen's domain 3 contains a cell binding site and a site that 

modified thrombin activation of platelets. Blood. 78 (Suppl 1): 217a, 1991. * 

43. Heda, G.D., Schmaier, A.H. Induction of HEP G2 cell C1 inhibitor by gamma interferon is 

mediated by serine/threonine kinases. Blood. 78 (Suppl 1):76a , 1991.* 

44. Zini, J-M., Schmaier, A., Cines, D. Bradykinin stimulates the binding of its precursors, high and 

low molecular weight kininogens, to human endothelial cells. Blood. 78 (Suppl 1): 75a, 1991.* 

45. Schmaier, A.H., Dahl, L.D., Wang, K., Van Nostrand, W. Human platelet calpain proteolyzes the 

amyloid precursor protein to liberate -amyloid. Circ 86(4):151, 1992.* 

46. Schmaier, A.H., Dahl, L.D., Rozemuller, J.M., Roos, R.A.C., Wagner, S.L., Van Nostrand, W. 

Protease Nexin-2/amyloid precursor protein is a tight-binding inhibitor of factor IXa. Blood 80 

(Suppl 1):262a, 1992.* 

47. Jiang, Y.P. and Schmaier, A.H. Expression of recombinant thrombin-inhibitory domain of 

kininogen in ESCHERICHIA COLI. Blood 80 (Suppl 1):309a, 1992.* 

48. Jiang, Y.P., Hasan, A.A.K., Schmaier, A.H. Characterization of human kininogens purified by 

Blue Sepharose. Blood 80 (Suppl 1):490a, 1992. 

49. Hasan, A.A.K., Cines, D.B., Schmaier, A.H. Kininogen regulates endothelial cell biology by 

surface binding alone. Thromb Haemost. 69:782, 1993.* 

50. Schmaier, A.H., Dahl, L.D., Van Nostrand, W.E. Factor VIIIa protects factor IXa from inhibition 

by protease nexin-2/amyloid -protein precursor. Thromb Haemost. 69:984, 1993.* 

51. Hasan, A.A.K., Cines, D.B., Schmaier, A.H. Bradykinin in high molecular weight kininogen (HK) 

participates as an endothelial cell binding domain. Blood. 82 (Suppl 1):148a, 1993.* 

52. Amenta, S. Schmaier, A.H. Contact activation contributes to plasmin generation in acute attacks of 

angioedema of C1 inhibitor deficient patients. Blood. 82 (Suppl 1):280a, 1993.*


53. Gluszko, P., Undas, A., Amenta, S., Szczeklik, A., Schmaier, A.H. Administration of gamma 

interferon in man decreases plasminogen activation and fibrinolysiswithout influencing C1 

inhibitor. Blood. 82 (Suppl 1):411a, 1993.* 

54. Schmaier, A.H., Hasan, A.A.K., Amenta, S., Cines, D.B. Bradykinin (BK) modulates the 

expression of kininogens (KG) on endothelial cells (HUVEC). The FASEB J.8:A352, 1994.* 

55. Schmaier, A.H., Dahl, L.D., Hasan, A.K.K., Cines, D.B., Van Nostrand, W.E. Platelets and 

endothelial cells modulate protease nexin-2/amyloid precursor protein's (PNinhibit 

factor IXa. Clin Res. 42:183A, 1994.* 

56. Motta, G., Hasan, A.A.K., Cines, D.B., Schmaier, A.H. Prekallikrein assembly on endothelial cells 

facilitates prourokinase activation. Thromb. Haemost. 73:148, 1995.* 

57. Mahdi, F., Van Nostrand, W.E., Schmaier, A.H. Protease nexin-2/amyloid - precursor protein is 

an inhibitor of factor Xa. Thromb. Haemost. 73:1261, 1995.* 

58. Hasan, A.A.K., Amenta, S., Schmaier, A.H. Bradykinin and related peptides selectively inhibit - 

thrombin's ability to activate the platelet thrombin receptor. Thromb. Haemost. 73:924, 1995.* 

59. Kehoe, K.J., Mahdi, F., Heda, G.D., Schmaier, A.H. Gamma interferon's upregulation of C1 

inhibitor mRNA is modulated by both genistein and cantharidin. Blood. 86 (Supple 1):360a, 

1995.* 

60. Motta, G., Hasan, A.A.K., Cines, D.B., Schmaier, A.H. High molecular weight kininogen and 

prekallikrein assembly on endothelial cells produce plasminogen activation independent of factor 

XII. Blood. 86 (Supple 1):374a, 1995.* 

61. Gitlin, S.D., Deeb, G.M., Schmaier, A.H. Heart transplantation in a patient with heparin-associated 

thrombocytopenia. Blood. 86 (Supple 1):871a, 1995. 

62. Hasan, A.A.K., Rebello, S.S., Wahl, R., Fisher, S.J., Lucchesi, B.R., Schmaier, A.H. 

Thrombostatin: in vivo clearance and effect of this thrombin receptor inhibitor. Circulation 

94:I229, 1996.* 

63. Schmaier, A.H., Mahdi, F., Van Nostrand, W.E., Rehemtulla, A. Protease nexin- - 

protein precursor inhibits factor VIIa-tissue factor in the tenase complex. Blood. 88 (Supple 1): 

521a 1996.* 

64. Hasan, A.A.K., Zisman, T., Schmaier, A.H. Cytokeratin 1 is the major endothelial cell receptor for 

kininogens. Thromb. Haemostasis. 77(Supplement 1):141, 1997.* 

65. Shariat-Madar, Z., Mahdi, F., Rojkjaer, R., Schmaier, A.H. Mapping of the kininogen binding 

domain on its endothelial cell receptor, cytokeratin 1. Blood. 90 (Suppl 1):79b, 1997. 

66. Rojkjaer, R., Hasan, A.A.K., Schousboe, I., Schmaier, A.H. Factor XII is not essential 

for contact activation on endothelial cells. Blood. 90 (Suppl 1):79b, 1997. 

67. Annich, G., White, T., Damm, D., Zhao, Y., Mahdi, F., Meinhardt, J., Rebello, S., Lucchesi, B., 

Bartlett, R.H., Schmaier, A.H. Reco - 

protein precursor as an anticoagulant for extracorporeal circulation in rabbits. Circ 98 (Suppl 1):I- 

728, 1998*. 

68. Hasan, A.K.K, Krishnan, R., Tulinsky, A., Srikanth, S., Schmaier, A.H. The mechanism of 

thrombostatin’s inhibition of thrombin-induced platelet activation. Circ 98 (Suppl 1): I-800, 

1998*. 

69. Rojkjaer, R., Hasan, A.A.K., Schmaier, A.H. A novel mechanism for factor XI activation on 

endothelial cells independent of autoactivation, -thrombin, or factor XIIa. Blood. 92 (Supple


1):40a, 1998.* 

70. Rojkjaer, R., Schmaier, A.H. Regulation of kallikrein, factor XIa and factor XIIa activity on 

endothelial cell membranes. Thromb Haemost. Suppl 8/99:33, 1999* 

71. Hasan, A.A.K., Srikanth, S., Smith, E., Werns, S., Driscoll, E., Brenner, D., Normolle, D., 

Lucchesi, B.R., Schmaier, A.H. Thrombostatin-A thrombin receptor activation inhibitor; 

mechanism 

of action, and in vivo efficacy. Thromb Haemost. Suppl 8/99:414, 1999* 

72. Hasan, A.A., Schmaier, A.H., Warnock, M., Normolle, D., Driscoll, E., Lucchesi, B.R., Werns, 

S.W. Thrombostatin inhibits cyclic flow variations in the Folts model of canine coronary artery 

thrombosis. Blood. 96 (Suppl 1):52a, 2000.* 

73. Mahdi, F., Shariat-Madar, Z., Rojkjaer, R., Todd III, R.F., Figueroa, C., Schmaier, A.H. 

Expression and co-localization of cytokeratin 1 and urokinase plasminogen activator receptor on the 

membrane of endothelial cells. Blood. 96(Suppl 1):42a, 2000.* 

74. Mahdi, F., Shariat-Madar, Z., Figueroa, C.D., Schmaier, A.H. Factor XII interacts with the 

multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on 

endothelial cell membranes. Blood. 98:245a, 2001.* 

75. Hasan, A.A.K., Warnock, M., Srikanth, S., Mahdi, F., Krishnan, R., Tulinsky, A., Schmaier, A.H. 

The mechanisms of thrombostatin inhibition of thrombin. Blood. 98:530a, 2001.* 

76. Krijanovski, Y., Mahdi, F., Proulle, V., Dreyfus, M., Kerbirious-Nabias, D., Schmaier, A.H. High 

molecular weight kininogen deficient patient with a single basepair deletion in the surface binding 

region of domain 5. Blood. 98:530a-531a, 2001.* 

77. Shariat-Madar, Z., Mahdi, F., Schmaier, A.H. Identification and characterization of 

prolylcarboxypeptidase as an endothelial cell prekallikrein activator. Blood. 98:753a, 2001.* 

78. Shariat-Madar, Z., Mahdi, F., Schmaier, A.H. Recombinant prolylcarboxypeptidase (rPRCP) 

activates plasma prekallikrein. Blood. 100:485a, 2002*. 

79. Srikanth, S., Krijanovski, Y. Schmaier, A.H. Reduced rate of bradykinin metabolism protects the 

mouse from thrombosis. Blood. 100:24a, 2002*. 

80. Schmaier, A.H., Warnock, M., Hasan, A.A.K., Nieman, M.T. Preparation and characterization of 

new Thrombostatins – antagonists to activation of protease-activates receptors and thrombin. 

Blood. 102:164a- 165a, 2003.* 

81. Nieman, M.T., Pagan-Ramos, E., Schmaier, A.H. Structural requirements of thrombin’s 

interaction with PAR1 and PAR4 exodomains. Blood. 102:300a-301a, 2003.* 

82. Schmaier, A.H., Pagan-Ramos, E., Warnock, M, Krijanovski, Y., Hasan, A.A.K. Arg-Pro-Pro-Gly- 

Phe binds to the exodomain of human protease activated receptor 4 (PAR4) to prevent thrombin 

proteolysis and platelet activation. Blood. 102:776a-777a, 2003*. 

83. Nieman, M.T., Kalikin, L., McCauley, L., Pienta, K.J., Schmaier, A.H. Thrombin contributes to 

tumorigenic properties of prostate cancer cells and thrombostatin modifies these effects. Blood. 

102:780a-781a, 2003*. 

84. Rectenwald, J.E., Myers, D.D., Hawley, A.E., Gangireddy, C.R., Henke, P.K., Guire, K.E., 

Schmaier, A.H., Wakefield, T.W. D-Dimer, P-Selectin, and Microparticles: Novel Markers to 

Predict Deep Venous Thrombosis Blood. 104:714a, 2004* 

85. Nieman, M.T., Pagan-Ramos, E., Warnock, M., Krijanovski, Y., Hasan, A.A.K., Schmaier, A.H. 

Mapping the interaction of peptide RPPGF with the exodomain on human protease activated 

receptor (PAR4). Blood. 104:511a-512a, 2004* 

86. Shariat-Madar, Z., Warnock, M., Mahdi, F., Srikanth, S., Krijanovski, Y., Schmaier, A.H., 

Angiotensin receptor2 over-expression: a novel physiologic mechanism for thrombosis protection. 

Blood. 104:229a, 2004*


87. Mahdi, F., Shariat-Madar, Z., Schmaier, A. Outside-In signaling upon assembly on endothelial cell 

of the Proteins of the Kallikrein/Kinin System. Blood. 106 (Suppl), 2005.* 

88. Nieman, M.T., Schmaier, A.H. The contributions of the P4-P2 positions in PAR1 and 4 for 

Thrombin Receptor Cleavage. Blood. 106 (Suppl), 2005.* 

89. Shariat-Madar, Z., Rahimy, E., Mahdi, F., Schmaier, A.H. Over-expression of 

prolycarboxpeptidase 

enhances plasma prekallikrein activation on Chinese Hamster ovary cell membranes. Blood. 106 

(Suppl), 2005.* 

90. Schmaier, A.H., Mahdi, F., Sitrin R. The urokinase plasminogen activator receptor mediates 

ScuPA- or FXII-induced cell growth and proliferation. Blood. 108 (Suppl), 2006.* 

91. Adams, G.N., Zhou, Y., Larusch, G., Nieman, M.T., Hoit, B., Jacobs, G., Yu, X., Mahdi, F. 

Shariat-Madar, Z., D’Alecy, L.D., Okada, Y., Schmaier, A.H. Prolylcarboxypeptidase murine 

hypomorphs are hypertensive and prothrombotic. Abstract, ASH 12/8/2008.* 

92. Larusch, G., Mahdi, F., Shariat-Madar, Z., Adams, G.N., Sitrin, R., Zhang, W., McCrae, K.R., 

Schmaier, A.H. Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to 

initiate angiogenesis. Blood 114: Issue 22: 1184, 2009.* 

93. Adams GN, LaRusch G, Stavrou E, Zhou Y, Nieman MT, Jacobs G, Cui Y, Lu Y, Jain MK, Mahdi 

F, Shariat-Madar Z, D’Alecy LG, Schmaier AH. Prolylcarboyxpeptidase deficiency is a risk factor 

for arterial thrombosis and hypertension. Amer Soc Hematol abstracts, December, 2010 * 

94. Fang C, Schmaier A, Stavrou E, Adams G, Nieman MT, LaRusch G, Chen A, Zhou Y, Bilodeau M, 

Mahdi F, Warnock M, Schmaier AH. Bradykinin B2 receptor KO mice are protected from 

thrombosis by a platelet spreading defect. Amer Soc Hematol abstracts, December, 2010 * 

95. Stavrou E, LaRusch GA, Fullana MJ, Wnek GE, Qu C-K, Yu W-M, Meyerson HJ, Fang C, Ziats N, 

Schmaier AH. Factor XII promotes leukocyte inflammation and its deficiency results in faster 

wound healing. Amer Soc Hematol abstracts, December, 2011* 

96. Fang C, Stavrou E, Schmaier AA, Adams GN, Nieman MT, LaRusch GA, Bilodeau M, Mahdi F, 

Chen A, Schmaier AH. Over-expression of the Mas receptor decreases arterial thrombosis risk in 

B2R KO mice by elevating NO and prostacyclin and reducing GPVI activation. Amer Soc Hematol 

abstracts, December, 2011* 

97. Adams GN, LaRusch GA, Schmaier AH. Prolylcarboxypeptidase promotes endothelial cell 

proliferation and vascular repair. Amer Soc Hematol abstracts, December, 2011* 

*Presented at National/International Meetings


TRAINEES 

Post-Doctoral Trainees 

Trainee Degree Institution Position in Current Position 

my laboratory (years) 

Gustafson EG MD U of Illnois Post-doc (‘84-’87) Private Practice in Hematology/ 

Oncology 

Meloni FJ PhD Bryn Mawr College Post-doc (‘87-’91) McNeil Pharmaceuticals 

Heda G PhD Osmania U Res. Assist. Prof Assist. Prof., Miss U for Women. 

(‘87-’91) Dept of Biology; NIH funded 2011 

Mardenta S MD U of Rome Post-doc (‘88-’89) Res. Assoc., U of Rome 

Nawarawong W MD Chiang Mai Post-doc (‘90-’91) Professor, Chiang Mai University 

University Chiang Mai, Thailand 

Jiang, YP PhD. Rutgers U. Res. Assit. Prof Business, Peoples Republic of 

(‘90-’93) China 

Hasan AAK MD, PhD Institute Cardio Res. Invest. (‘91-’97) Program Director (’02) 

Moscow, USSR Asst Res. Sci (‘97-‘02 ( NHLBI, Blood Resources 

University of Michigan National Institutes of Health 

Assoc Direct: Atherosclerosis 

Amenta S MD Aristoteleion U Post-doc (‘91-’94) Private Practice 

Kehoe K PhD U of Michigan Post-doc (‘92-’94) Assistant. Professor., 

Jacksonville Univ. 

Motta G PhD Escola Paulista de Post-doc (‘94-’96) Assoc. Prof., Escola Paulista de Medicina 

Medicina Sao Paulo, Brazil 

Shariat-Madar Z PhD Medical Coll Post-doc (‘97-’98) Assistant Professor (’05) 

of Toledo Res Invest (’98-’03) of Pharmacology 

Res Assist Prof (’03-’05) University of Michigan 

Assist Prof Pharm (’05-Present) Univ of Mississippi 

NSF & NIH P50 funding 

Ameri A MD U of Marburg Post-doc (‘97-99) Assit. Prof of Pediatrics 

Medical College of Georgia 

Smith E MD MSU Post-doc (‘97-’98) Private Practice in Hematology/ 

Oncology 

Rojkjaer R PhD U of Copenhagen Post-doc (‘97-‘00) Nova Pharmaceuticals 

Zhao Y MD Peking U Med Coll Post-doc (‘97-’98) Assoc. Prof., Peking Union Medical 

College, Beijing, P.R. China 

Qui Q MD Shanghai Med Coll Post-doc (‘98-‘00) Post-doctoral fellow, Wayne State 

University 

Krijanovski Y MD Russian State Med U Post-doc (‘00-’02) Clinical Hematology/Oncology


Schlemmer, Scott PhD Cornell University Post-doc (’06) Biotek Industry, Akron, OH 

Nieman, Marvin PhD Medical College of Post-doc (’03-06) Assist Prof, CWRU, Dept of Pharmacol 

Toledo R01 funded, 2010 

Chen, Andrew MD Thomas Jefferson U Post-doc (’07-09) EP Fellow, Cardiology Yale U 

Stavrou, Evi MD Semmelweis U Post-doc (’09-‘11) Instructor, CWRU, Dept of Med 

Hematology & Oncology 

Pre-Doctoral Students 

Pinto, Clauda RM Escola Paulista de Pre-doc (’01) Ph.D. in Biochemistry 

Medicina 

Ting Ting Hong U of Michigan, Dept Pharmacology Thesis Committee 2003 

Reynolds, Justin M. University of Michigan Medical Student 2003 

Michigan 

Xiaoyun Chen U of Michigan, Depart of Chemistry Thesis Committee 2004 

Fernanda Marques U of Michigan, Depart of Med Chem Medicinal Chem Grad Student 

Wolfram, Julie Case Western. Reserve U. BSTP graduate student 

Hirbawi, Jamila Cleveland State U, Depart of Biochem Thesis Committee, 2007 

Joseph Swiegert Case Western Reserve U Medical Student 2007 

Gregory Adams Case Western Reserve U Pathology Grad Student 2007- 

Jacob McGrath Case Western Reserve U. Medical Student 2008 

Chao Fang Case Western Reserve U Pathology Grad Student 2008 

Gretchen Lockhart U of Cincinnatti Medical Student 2010 

Cindy Chen UC Irvine Medical Student CWRU 2012 

Samatha Zweibel U of Chicago Medical Student CWRU 2012 

Undergraduate Trainees 

Zisman, Timothy BA U of Michigan Trainee ’94-’98 MD, Medical Resident, U of 

Chicago 

Spalding, Aaron BA U of Michigan Trainee ’96-’98 MD-PhD, Resident, U of 

Michigan 

Ferdoriw, Larysa BA U of Michigan Trainee ’01-’02 Candidate for MPH, U of 

Illinois 

Bolterstein, Bridget BA U of Michigan Trainee ’01-‘03 Pharm. Representative 

Syed Younis BS Columbia U Trainee Summer ’02 Business School 

Kasper, Nicole BA U of Michigan Trainee ’02-‘04 Grad Student, Public Health 

Rahimy, Ehsan BS U of Michigan Trainee ’03-’04 Med. Student, Baylor Col of 

Medicine


Haghshenas, Jafar BA U of Michigan Trainee ’04-05 Med Student, U of Michigan 

Walton, David BA U of Michigan Trainee ’05 Med Student, Case Western 

Reserve University 

McCrae, Bret BA Brown University Trainer ’06,’07 Undergraduate 

Brown U 

Brodsky, David Case W. Reserve U. Undergraduate Project ’06 

Daniel Ricketts BA Brown University Trainee ’07 Undergraduate Brown U 

J. Eric Questel BA Xavier University Trainee ’08 Undergraduate Xavier U 

Kamari Jackson Ohio State University Trainee ’12 Undergraduate OSU

michigan cv - Case Western Reserve University - School of Medicine

Create successful ePaper yourself

Delete template?

Save as template?